

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)

Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00004729	Dan Kadrmaz	Co-Investigator	IRB_00031335	Multi-Tracer PET Assessment of Primary Brain Tumors	The investigator's licensed intellectual property will be used in the study. The nvestigator has significant financial interest in the licensing company.	no			yes	MultiFunctional Imaging, LLC	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00012418	James Hotaling	Co-Investigator	IRB_00073305	Preliminary investigation of erectile function using a non-invasive measurement device	The investigator has an equity interest in Andro360, the company whose device will be evaluated in this study.	no			yes	Andro360	Value cannot be readily determined	no	
CRV_00013955	Anne Blaschke	Co-Investigator	IRB_00049682	Molecular Classification of Pediatric Cancer	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00013956	Anne Blaschke	Co-Investigator	IRB_00042895	PARAPNEUMONIC EMPYEMA: USE OF MOLECULAR METHODS TO IDENTIFY PATHOGENS AND OUTCOME	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00013963	Anne Blaschke	Co-Investigator	IRB_00047322	Molecular Evaluation of Pediatric Joint Fluid	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00022401	Anne Blaschke	Principal Investigator	10035912	FilmArray Direct: Rapid Diagnosis of Antimicrobial-Resistant Pathogens from Blood	The investigator's licensed intellectual property will be evaluated in this study.	no			no			yes	Value cannot be readily determined
CRV_00023765	cheryl wright	Co-Investigator	IRB_00082197	The Evaluation of a Peer-Teaching Technology Education Program for Youth on the Autism Spectrum	The investigator's licensed intellectual property will be used in the study. The nvestigator has significant financial interest in the licensing company.	no			yes	NeuroVersity	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00025491	Sujeevini Jeyapalina	Co-Investigator	IRB_00073178	Microbiome and Innate Immunity with Percutaneous Osseointegrated Prostheses	The investigator's licensed intellectual property will be evaluated in the study.	no			no			yes	Value cannot be readily determined
CRV_00036664	Anne Blaschke	Co-Investigator	IRB_00089825	FilmArray Direct: Rapid Diagnosis of Antimicrobial-Resistant Pathogens from Blood	The investigator's licensed intellectual property will be evaluated in the study.	no			no			yes	Value cannot be readily determined
CRV_00037314	Ken Johnson	Co-Investigator	IRB_00090093	Comparison of Effect Site Concentrations of Anesthetic Agents with Processed Electroencephalography	The investigator has licensed intellectual property that will be evaluated in the study. The investigator has an equity interest in Medical Visualizations, which holds the license to the intellectual property.	no			yes	Medical Visualizations	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00040825	Jeremy Gililland	Principal Investigator	IRB_00091705	Fluoroscopic Grid use in Total Hip Arthroplasty	The investigator has an equity interest in OrthoGrid Technologies, whose technology is being evaluated in the study. The investigator also discloses he is a co-inventor of the technology.	no			yes	OrthoGrid Technologies	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00048955	Mark Yandell	Co-Investigator	IRB_00088405	GENETIC EPIDEMIOLOGY OF HEMATOLOGICAL MALIGNANCIES	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00049463	Gabor Marth	Co-Investigator	IRB_00065564	Utah Genome Project	The investigator's intellectual property is being used in the research, and is exclusively licensed to Frameshift Labs (a non-publicly company in which the investigator has significant equity interest).	no			yes	Frameshift Labs	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00050595	Robert Schlaberg	Co-Investigator	IRB_00097639	Metagenomic approach to the evaluation of myocarditis	The investigator's intellectual property will be used in study. It has been licensed to IDbyDNA, a non-publicly traded company in which the investigator has significant equity interest as founder.	no			yes	IDbyDNA	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00052162	Jeremy Gililland	Principal Investigator	IRB_00098977	Intraoperative Data Collection for the use of a Novel Digital Fluoroscopic Grid	The investigator has a significant interest in OrthoGrid, the study sponsor and manufacturer of the investigational device used in the study.	no			yes	OrthoGrid	Value cannot be readily determined	no	

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)						Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest							
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00052546	Robert Schlager	Principal Investigator	IRB_00099611	Reproducibility of pathogen detection by metagenomics	The investigator's intellectual property, Taxonomer, will be used in study. It has been licensed to IDbyDNA, a non-publicly traded company in which the investigator has significant equity interest as founder.	no			yes	IDbyDNA	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00055929	K-T VARLEY	Principal Investigator	10039059	A partnership to enable clinical ctDNA testing for breast cancer recurrence	The investigator has significant financial interests (employment remuneration and equity interest) in Kailos Genetics, a non-publicly traded company that will partner with the Varley Lab at University of Utah to conduct this research. The investigator reports her intellectual property will be developed and used in this study.	yes	Kailos Genetics	\$20,000-39,999	yes	Kailos Genetics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00056856	Sean Runnels	Principal Investigator	IRB_00090403	Airway exchange catheter tip control in the trachea with and without videolaryngoscopy in airway mannequins	The investigator has a significant interest in "Through the cords, LLC," a non-publicly traded company whose technology is being evaluated in the study.	no			yes	Through the cords	Value cannot be readily determined	no	
CRV_00057481	Eric Schmidt	Principal Investigator	10042382	Symbiosis and Chemical Diversity Generation	The investigator's licensed intellectual property will be used in the study. The intellectual properties are licensed to Synthetic Biodesign, a non-publicly traded company in which the investigator has a significant equity interest.	no			yes	Synthetic Biodesign	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00059352	James Hotaling	Co-Investigator	IRB_00072148	Validation study of urine flow rate monitoring with novel device: StreamDx.	The investigator's intellectual property is being used in the study. It has been exclusively licensed to StreamDX, a non-publicly traded company in which the investigator has significant equity interest.	no			yes	StreamDX	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00060157	Gabor Marth	Principal Investigator	IRB_00103793	Web tools to enhance physician-driven diagnostic interpretation of genomic patient data	The investigator's intellectual property will be evaluated in the research, and has been exclusively licensed to Frameshift Labs (a non-publicly traded company in which the investigator has significant equity interest).	no			yes	Frameshift Labs	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00060690	Zachary Imel	Principal Investigator	10041107	Implementation of Technology-based Evaluation of Motivational Interviewing	The investigator's intellectual property is being used in the research. The investigator reports an equity interest in Lyssn.io, which will be commercializing the intellectual property.	no			yes	Lyssn.io	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00060893	Mark Yandell	Co-Investigator	10043756	Software for exploring all forms of genetic variation in any species	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00061132	Gabor Marth	Principal Investigator	10042890	IOBIO: Web-based, interactive tools for real-time analysis in genomic big data	The investigator's intellectual property will be used in the research, and has been exclusively licensed to Frameshift Labs (a company in which the investigator has a significant equity interest).	no			yes	Frameshift Labs	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00061593	James Hotaling	Principal Investigator	10043586	Stream Dx: accurate and efficient, point-of-care uroflometry for improved diagnosis, monitoring, and post-treatment evaluation of LUTS	The investigator's intellectual property is being used in the study. It has been exclusively licensed to StreamDX, a non-publicly traded company in which the investigator has a significant equity interest.	no			yes	StreamDx	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00062071	Mark Yandell	Co-Investigator	10044535	The Genetics of Primary Ovarian Insufficiency	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)

Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00062080	Michael Tanana	Data Analyst	IRB_00083132	Implementation of Technology-Based Evaluation of Motivational Interviewing	The investigator has a significant equity interest in Lyssn.io, a non-publicly traded company which will be commercializing the intellectual property used in the study.	no			yes	Lyssn.io	Value cannot be readily determined	no	
CRV_00062081	Zachary Imel	Principal Investigator	IRB_00083132	Implementation of Technology-Based Evaluation of Motivational Interviewing	The investigator's intellectual property is being used in the research. The investigator reports a significant equity interest in Lyssn.io, a non-publicly traded company which will be commercializing the intellectual property.	no			yes	Lyssn.io	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00062097	Gabor Marth	Principal Investigator	10043785	Web tools for physician-driven diagnostic interpretation of genomic patient data	The investigator's intellectual property will be evaluated in the research. The intellectual property is licensed to Frameshift Labs, a non-publicly traded company in which the investigator has a significant equity interest.	no			yes	Frameshift Labs	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00063164	Michael Kay	Co-Investigator	10044932	Center for the Structural Biology of Cellular Host Elements in Egress, Trafficking, and Assembly of HIV (CHEETAH Center)	The investigator's intellectual property will be used in the research. Commercialization may be imminent through Navigen, a company in which the investigator has significant equity interest and consulting remuneration.	yes	Navigen	\$10,000-19,999	yes	Navigen	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00063610	Lucinda Bateman	Co-Investigator	IRB_00098946	Using the UPDB to Increase Understanding of Chronic Fatigue Syndrome and Fibromyalgia	The investigator has a significant financial interest in Bateman Horne Center of Excellence, where electronic records will be obtained from in the study.	yes	Bateman Home Health Center for Excellence	\$80,000-\$99,999	no			no	
CRV_00063833	Kerry Kelly	Principal Investigator	10042257	AirU: Community Network to Understand Air Quality and Sensor Reliability	The investigator's intellectual property is being used in the study, and commercialization may be imminent through Tetrad: Sensor Network Solutions (a company in which the investigator has significant equity interest).	no			yes	Tetrad: Sensors Network Solutions	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00064098	Stephen Summers	Principal Investigator	10043586	Stream Dx: accurate and efficient, point-of-care uroflometry for improved diagnosis, monitoring, and post-treatment evaluation of LUTS	The investigator reports significant equity interest in StreamDx, the study sponsor.	no			yes	StreamDx	Value cannot be readily determined	no	
CRV_00064292	Scott Summers	Co-Investigator	10043577	Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases	The investigator has a significant financial interest in Centaurus Therapeutics, which is a subsidiary of the study sponsor Potrero Hill Therapeutics.	yes	Centaurus Therapeutics	\$10,000-19,999	yes	Centaurus Therapeutics	Value cannot be readily determined	no	
CRV_00064808	Robert Schlager	Co-Investigator	IRB_00103100	Metagenomics Approach to the Evaluation of Kawasaki Disease	The investigator's intellectual property will be used in the study. It has been exclusively licensed to IDbyDNA, a non-publicly traded company in which the investigator has a significant equity interest.	yes	IDbyDNA	\$60,000 to \$79,999	yes	IDbyDNA	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00065014	Brook Martin	Principal Investigator	10045701	The Influence of an expanded bundled payment program on patient-reported outcomes, episode-of-care costs, procedure volume, and safety.	The investigator reports significant equity interest in Statix, LLC (formerly known as Gold Standard Research), a non-publicly traded company which was contracted for use of their web-enabled content management system to help collect patient-reported outcomes. Per investigator, secondary analysis of this data will be performed in this study.	no			yes	Statix, LLC	Value cannot be readily determined	no	

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)						Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest							
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00065016	Brook Martin	Principal Investigator	IRB_00099871	Influence of an expanded mandatory bundled payment program on patient-reported outcomes, episode-of-care costs, procedure volume, and safety.	The investigator reports significant equity interest in Statix, LLC (formerly known as Gold Standard Research), a non-publicly traded company which was contracted for use of their web-enabled content management system to help collect patient-reported outcomes. Per investigator, secondary analysis of this data will be performed in this study.	no			yes	Statix, LLC	Value cannot be readily determined	no	
CRV_00066434	Kent Bachus	Principal Investigator	10045959	Percutaneous Osseointegrated Docking System for Above Elbow Amputees...IPA Castolene	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00066439	Sean Runnels	Principal Investigator	IRB_00095038	THE EFFECTS OF A UNIQUE COLOR ZONE SYSTEM ON ENDOTRACHEAL TUBE DEPTH CONTROL DURING EMERGENCY INTUBATIONS WITH VIDEO LARYNGOSCOPY IN AIRWAY MANNEQUINS	The investigator reports significant equity interest as Founder/CMO of "Through the cords, LLC," a non-publicly traded company whose technology is being evaluated in the study.	no			yes	Through the cords	Value cannot be readily determined	no	
CRV_00066629	Kent Bachus	Principal Investigator	IRB_00011755	Biomechanical Testing of Orthopaedic Devices Using Decedent Tissue Models	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00066990	Kent Bachus	Principal Investigator	IRB_00065516	The variability of the residual bone and soft tissues of amputated extremities following traumatic amputation	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00067455	Florian Solzbacher	Co-Investigator	10033446	Revolutionizing Utah Array using Nanotechnology to Enhance Efficacy and Logevity	The investigator has a financial interest in the study sponsor Blackrock Microsystems. The investigator has intellectual property being used in the study.	yes	Blackrock Microsystems	>\$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00068823	K-T VARLEY	Co-Investigator	IRB_00041211	Cancer Genetics Study	The investigator's licensed intellectual property will be used in the study. The nvestigator has significant financial interest in the licensing company.	yes	Kailos Genetics	\$20,000-39,999	yes	Kailos Genetics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00069196	Robert Burks	Co-Investigator	IRB_00101394	Long Term Patient Reported Outcomes for the Shoulder and Elbow Population	The investigator's financial interests may be related to the broad aims of this research.	no			yes	KATOR	Value cannot be readily determined	no	
CRV_00069213	Mark Yandell	Co-Investigator	10036978	A Community Driven Framework for Genome Based Clinical Diagnostics	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00069222	Mark Yandell	Principal Investigator	10027982	VAAST+: Tool for variant prioritization, risk assessment and disease-gene finding	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00069223	Mark Yandell	Co-Investigator	10038816	Integrating Genomic and Clinical Approaches to Sudden Death in the Young	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00069226	Mark Yandell	Co-Investigator	10036824	Bridging the Gap between Genomics and Clinical Outcomes in CHD	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00069227	Mark Yandell	Co-Investigator	IRB_00084861	PEDIATRIC CARDIAC GENOMICS CONSORTIUM: CONGENITAL HEART DISEASE GENETIC NETWORK STUDY (CHD GENES)	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00069229	Mark Yandell	Co-Investigator	IRB_00066143	Biological Determinants of Brain Variation in Autism	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)

Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00069233	Mark Yandell	Co-Investigator	IRB_00021080	Pediatric Cardiology Genotype-Phenotype Core	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00069235	Mark Yandell	Co-Investigator	IRB_00006042	Genetics Of Autism	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00069236	Mark Yandell	Co-Investigator	IRB_00065564	Utah Genome Project	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00069474	Jeremy Gilliland	Co-Investigator	IRB_00075446	Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty	The investigator has a significant financial interest in Smith & Nephew, whose products may be analyzed in this study.	yes	Smith & Nephew	\$5,000-9,999	no			no	
CRV_00069707	Robert Tashjian	Principal Investigator	IRB_00046622	Functional and Radiographic Outcomes after Shoulder Surgery	The investigator's financial interests may be related to the broad aims of this research.	yes	Shoulder Innovations, Wright Medical Technology, Zimmer Biomet	\$40,000-59,999; \$10,000-19,999; \$10,000-19,999	yes	Shoulder Innovations, Wright Medical Technology	Value cannot be readily determined	no	
CRV_00069808	Scott Summers	Principal Investigator	10045278	The Role of Ceramides in Skeletal Muscle	The investigator has significant financial interests (remuneration and equity interest) in Centaurus Therapeutics, a non-publicly traded company whose pharmacological compounds will be evaluated in the study.	yes	Centaurus Therapeutics	\$20,000-39,999	yes	Centaurus Therapeutics	Value cannot be readily determined	no	
CRV_00070987	Dennis Parker	Co-Investigator	10045663	Validation and translation of a non-invasive, MR-guided breast cancer therapy	The investigator's licensed intellectual property will be used in the research.	no			no			yes	Value cannot be readily determined
CRV_00070993	Allison Payne	Principal Investigator	10045663	Validation and translation of a non-invasive, MR-guided breast cancer therapy	The investigator's licensed intellectual property will be used in the research.	no			no			yes	Value cannot be readily determined
CRV_00071050	Mark Yandell	Co-Investigator	IRB_00096990	GENETIC EPIDEMIOLOGY OF BREAST CANCER	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00071083	Stephen Summers	Principal Investigator	IRB_00072148	Study of urine flow rate monitoring with novel device: Stream Dx.	The investigator has a significant financial interest in StreamDx, whose device is being investigated in the study.	no			yes	StreamDx	Value cannot be readily determined	no	
CRV_00071131	Doug Christensen	Co-Investigator	10045663	Validation and translation of a non-invasive, MR-guided breast cancer therapy	The investigator's licensed intellectual property will be used in the research.	no			no			yes	Value cannot be readily determined
CRV_00071192	Leslie Jerominski	Co-Investigator	IRB_00044244	Genetic risk factors in suicide and depression	The investigator has a significant financial interest in Janssen Research & Development, a company that is collaborating in the data analysis portion (epidemiological and genetic analyses) of the study.	yes	Janssen Pharmaceutical Inc	\$5,000-9,999	no			no	
CRV_00071953	Mark Yandell	Principal Investigator	10047926	Whole Genome Sequencing-Based Discovery of Genes for Diabetic Kidney Disease	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00072556	Natalie Silvertown	Principal Investigator	IRB_00104747	Noninvasive measurements of renal perfusion during cardiac surgery	The investigator's licensed intellectual property will be used in the study. The nvestigator has significant financial interest in the licensing company.	no			yes	KSCube	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00073182	Anthony Donato	Principal Investigator	10041258	Novel Methodology for Identification of Senolytics that Reduce Age-Related Disease and Dysfunction	The investigator has a significant financial interest in Recursion Pharmaceuticals, the study sponsor.	no			yes	Recursion Pharmaceuticals	Value cannot be readily determined	no	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)

Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00073209	Mei Yee Koh	Principal Investigator	10046473	A novel approach for the selective inhibition of HIF-2a in kidney cancer	The investigator has a significant financial interest in Kuda Therapeutics, a non-publicly traded company which will provide some test compounds for use in the study.	no			yes	Kuda Therapeutics	Value cannot be readily determined	no	Value cannot be readily determined
CRV_00073315	Kai Kuck	Co-Investigator	IRB_00104747	Noninvasive measurements of renal perfusion during cardiac surgery	The investigator's intellectual property will be used in the study, and commercialization may now be imminent. The investigator has a significant financial interest with KSCube, the licensing company.	no			yes	KSCube	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00073456	Kai Kuck	Co-Investigator	10046431	Monitor to Detect Kidney Risk	The investigator's intellectual property will be used in the study, and commercialization may now be imminent. The investigator has a significant financial interest with KSCube, the licensing company.	no			yes	KSCube	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00073457	Natalie Silvertown	Principal Investigator	10046431	Monitor to Detect Kidney Risk	The investigator's intellectual property will be used in the study, and commercialization may now be imminent. The investigator has a significant financial interest with KSCube, the licensing company.	no			yes	KSCube	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00073736	Erik Jorgensen	Co-Investigator	10046566	Regulation of nutrient transporters	The investigator's licensed intellectual property will be used in the study. The investigator has a significant interest in Bruker, Inc., who holds a license on the intellectual property.	yes	Bruker Materials Group	\$10,000-19,999	no			yes	Value cannot be readily determined
CRV_00073806	Jeremiah Alt	Co-Investigator	10049369	A NOVEL GLYCOSAMINOGLYCAN-BASED THERAPEUTIC FOR CHRONIC RHINOSINUSITIS	The investigator has a significant financial interest in the study sponsor Glycomira, a non-publicly traded company.	no			yes	Glycomira Therapeutics	Value cannot be readily determined	no	
CRV_00074000	Jeremiah Alt	Principal Investigator	IRB_00074325	Sinonasal Tissue Repository	The investigator has a significant financial interest in Glycomira Therapeutics, a non-publicly traded company which will utilize specimens from this tissue bank for research.	no			yes	Glycomira Therapeutics	Value cannot be readily determined	no	
CRV_00074155	Gerald Krueger	Co-Investigator	IRB_00084288	Corrona-PSO-500 Corrona Psoriasis Registry	The investigator's financial interests may be related to the broad aims of this research.	yes	Abbvie, Eli Lilly, Johnson & Johnson, and Novartis	\$10,000-19,999; \$10,000-19,999;\$20,000-	no			no	
CRV_00074162	Hamid Ghandehari	Principal Investigator	IRB_00100644	The Hemocompatibility Study of Silica Nanoparticles as a function of Size and Surface Properties	The investigator's licensed intellectual property will be used in the research.	no			no			yes	Value cannot be readily determined
CRV_00074585	Karen Eilbeck	Co-Investigator	IRB_00013791	Utah Infertility Registry- Polycystic Ovary Syndrome (UIR-PCOS)	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	IDbyDNA; Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	IDbyDNA; Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00074587	Mark Yandell	Principal Investigator	IRB_00013791	Utah Infertility Registry- Polycystic Ovary Syndrome (UIR-PCOS)	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	IDbyDNA; Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	IDbyDNA; Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00074592	Mark Yandell	Principal Investigator	IRB_00100891	ENDOMETRIOSIS IMPRINTS (Infertility, Mortality (cancers), Pain, Reproductive outcomes (time to pregnancy, prematurity, preeclampsia, etc), Inheritance patterns (Is endometriosis one or multiple entities?), Noisome Traits (comorbidities) and Symptoms [IMP	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)

Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00074878	Jeremy Gilliland	Principal Investigator	10044965	INTRAOPERATIVE DATA COLLECTION FOR THE USE OF A NOVEL DIGITAL FLUOROSCOPIC GRID	The investigator has a significant interest in OrthoGrid, the study sponsor and manufacturer of the investigational device used in the study.	no			yes	OrthoGrid Technologies	Value cannot be readily determined	yes	
CRV_00074890	Mark Jensen	Co-Investigator	IRB_00100644	The Hemocompatibility Study of Silica Nanoparticles as a function of Size and Surface Properties	The investigator's licensed intellectual property will be used in the research.	no			no			yes	Value cannot be readily determined
CRV_00074906	Mark Yandell	Principal Investigator	IRB_00021614	Endometriosis: Natural History, Diagnosis, and Outcomes (ENDO)	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00074911	Mark Yandell	Co-Investigator	IRB_00017613	Familial kinship analysis in patients with Mullerian anomalies	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00075529	Swomitra Mohanty	Principal Investigator	10049671	EVALUATION OF A NOVEL BREATH SENSOR FOR RAPID, LOW-COST DIAGNOSIS OF TUBERCULOSIS IN CHILDREN	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in NanoSynth Materials and Sensors, which holds the license on the intellectual property.	no			yes	NanosSynth Materials and Sensors	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00075563	Philip Bernard	Co-Investigator	IRB_00096990	GENETIC EPIDEMIOLOGY OF BREAST CANCER	The investigator's licensed intellectual property will be used in the study. The investigator has a significant financial interest in Bioclassifier, which holds the license to the intellectual property.	no			yes	Bioclassifier, LLC	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00075628	Michael YU	Principal Investigator	10045626	TARGETING COLLAGEN MECHANICAL DAMAGE USING COLLAGEN HYBRIDIZING PEPTIDES	The investigator's licensed intellectual property will be used in the study. The investigator has a significant financial interest with 3Helix, a company that is commercializing the collagen hybridizing peptide used in this project.	no			yes	3Helix	Value cannot be readily determined	yes	
CRV_00075641	Martin McMahon	Principal Investigator	10046696	ELUCIDATING TUMOR PROGRESSION FACTORS IN MAPK-DRIVEN LUNG CANCERS	The investigator's licensed intellectual property will be used in the study.	no			no			yes	
CRV_00075882	Mark Yandell	Co-Investigator	IRB_00011467	A Feasibility Study for the Early Detection of Pancreatic Cancer	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00075900	Philipp Taussky	Principal Investigator	10036994	PROSPECTIVE STUDY ON EMBOLIZATION OF INTRACRANIAL ANEURYSMS WITH PIPELINE EMBOLIZATION DEVICE	The investigator has a significant financial interest in the study sponsor, Covidien, which has since been acquired by Medtronic.	yes	Medtronic	\$10,000-19,999	no			no	
CRV_00075904	Philipp Taussky	Co-Investigator	IRB_00082408	Outcomes of Pipeline Embolization Device for Intracranial Aneurysms	The investigator has a significant financial interest in the device manufacturer, Covidien, which has since been acquired by Medtronic.	yes	Medtronic	\$10,000-19,999	no			no	
CRV_00077037	Gerald Krueger	Co-Investigator	IRB_00108901	I4V-MC-JAIX - A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis	The investigator report significant financial interest with Eli Lilly, the study sponsor.	yes	Eli Lilly	\$10,000-19,999	no			no	
CRV_00077276	Karen Eilbeck	Data Analyst	IRB_00024408	Utah Markers of Risk: Endometriosis (MORENDO) A Longitudinal Sample Collection Study	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	IDbyDNA	\$60,001 to \$79,999	yes	IDbyDNA	Value cannot be readily determined	yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)					Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00077278	Mark Yandell	Principal Investigator	IRB_00024408	Utah Markers of Risk: Endometriosis (MORENDO) A Longitudinal Sample Collection Study	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	IDbyDNA	\$60,001 to \$79,999	yes	IDbyDNA	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00077398	Robert Schlager	Co-Investigator	10048317	METAGENOMICS APPROACH TO THE EVALUATION OF KAWASAKI DISEASE: A MULTICENTER PILOT STUDY	The investigator's licensed intellectual property will be used in the study. The nvestigator has significant financial interest in the licensing company.	yes	IDbyDNA	\$60,000-79. 999	yes	IDbyDNA	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00077527	Edward Dudek	Principal Investigator	10040726	Major reassessment of the fluid percussion and controlled cortical impact models of post-traumatic epilepsy	Investigator indicates that his intellectual property may be used in the study. The intellectual property is licensed to Epitel, a company in which the investigator has significant financial interest.	no			yes	Epitel	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00078925	Allison Payne	Principal Investigator	IRB_00114506	Validation of a Protocol for a Non-Invasive, Magnetic Resonance Guided Breast Cancer Therapy	The investigator's intellectual property will be evaluated in the study.	no			no			yes	Value cannot be readily determined
CRV_00078926	Dennis Parker	Co-Investigator	IRB_00114506	Validation of a Protocol for a Non-Invasive, Magnetic Resonance Guided Breast Cancer Therapy	The investigator's licensed intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00079416	Robert Schlager	Co-Investigator	IRB_00091019	EXEMPTION UMBRELLA: Anatomic Pathology Research Studies Using Archival Glass Slides and/or Formalin-fixed paraffin-embedded Blocks for Additional Testing.	The investigator's licensed intellectual property will be used in the study. The nvestigator has significant financial interest in the licensing company.	no			yes	IDbyDNA	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00079553	Dana DeWitt	Co-Investigator	IRB_00094516	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction (CHARM)	The investigator reports a significant financial interest in Biogen, the sponsor of the study.	yes	Biogen-Idec	\$5,000-9,999	no			no	
CRV_00079598	Krishna Sundar	Co-Investigator	IRB_00115678	Creation of "stable CPAP clinic" for population management of PAP-adherent sleep apnea patients through sleep coordinators.	The investigator reports a significant equity interest in Hypnoscore. The investigator's intellectual property, licensed to Hypnoscore, will be evaluated in the study.	no			yes	Hypnoscore	Value cannot be readily determined	yes	
CRV_00079617	Ravi Ranjan	Co-Investigator	IRB_00096657	AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial	The investigator has a significant financial interest in St. Jude Medical, the sponsor of the study.	yes	St. Jude Medical	\$5,000-9,999	no			no	
CRV_00082050	Christopher Peters	Co-Investigator	IRB_00116363	A Prospective Multicenter Longitudinal Cohort Study of the mymobility Platform	The investigator's intellectual property will be used in the study. The intellectual property is licensed to Zimmer Biomet, the study sponsor. The investigator receives remuneration Zimmer Biomet for consulting services.	yes	Zimmer Biomet	\$20,001 to 39,999	no			yes	Value cannot be readily determined
CRV_00085416	Glenn Prestwich	Co-Investigator	10049346	LOCALIZED DELIVERY OF GLYCOSAMINOGLYCAN ETHERS FOR THE TREATMENT OF RADIATION-INDUCED PROCTITIS	The investigator reports a significant equity interest with Glycomira Therapeutics, whose technology will be used in the project. The investigator is also an inventor of the technology licensed to Glycomira.	no			yes	Glycomira Therapeutics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00086263	Mark Yandell	Co-Investigator	IRB_00067518	Retrospective study of prognostic and predictive factors in advanced urologic cancers	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00086806	Alexander Pastuszak	Principal Investigator	10051699	CLINICAL MEN'S SEXUAL AND REPRODUCTIVE HEALTH FELLOWSHIP	The investigator reports a significant financial interest in Endo Pharmaceuticals, the sponsor of the project.	yes	Endo Pharmaceuticals	\$10,000-19,999	no			no	

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)					Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00086963	Florian Solzbacher	Principal Investigator	10047537	DEVELOPMENT AND TRANSLATION OF AN INTRACRANIAL AUDITORY NERVE IMPLANT	The investigator reports a significant financial interest in Blackrock Microsystems, who will be providing equipment for this project. The investigator's intellectual property licensed to Blackrock Microsystems will be used in the project.	yes	Blackrock Microsystems	>\$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00087879	Scott Summers	Principal Investigator	10051344	DIHYDROCERAMIDE DESATURASE-1 INHIBITORS FOR TREATMENT OF DIABETES AND OTHER METABOLIC DISEASES	The investigator reports a significant financial interest in Centaurus Therapeutics, which is owned by Potrero Hill Therapeutics, the sponsor of the project.	yes	Centaurus Therapeutics	\$10,000 to \$19,999	no			no	
CRV_00089246	Joshua Schiffman	Principal Investigator	10051735	ACCELERATING EP53 NANOPARTICLES FOR CANCER THERAPY	The investigator reports a significant financial interest in PEEL Therapeutics, the sponsor of the study. The investigators intellectual property will be used in this project.	yes	PEEL Therapeutics	\$60,000 to \$79,999	yes	PEEL Therapeutics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00092898	Florian Solzbacher	Principal Investigator	10053311	TRANSCEND: Transistor-Based Sensors to Capture Extracellular Fluid Dynamics	The investigator's intellectual property, licensed to Blackrock Microsystems (a company in which the investigator has a significant financial interest), will be used in the research project.	yes	Blackrock Microsystems	>\$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00093217	ALANA WELM	Co-Investigator	IRB_00010924	Molecular Classifications of Cancer	The investigator reports a significant financial interest in PhenoTx LLC, whose PDX models will be used in the project.	no			yes	PhenoTx, LLC	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00095904	Mark Yandell	Co-Investigator	IRB_00095807	A Pilot Study of Discovery-Driven Big Data Science: Empowering Evidence-Based Research to Improve the Value of Pediatric Cardiovascular Care	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	IDbyDNA; Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	IDbyDNA; Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00096257	Kai Kuck	Co-Investigator	IRB_00104924	Interactive Multimedia Diversion Device with Breath Control	The investigator reports a significant financial interest in CKC Medical, who manufactures the device being studied. The investigator's intellectual property is being used in this project. CKC Medical holds an option for the license on this technology.	no			yes	CKC Medical	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00096489	Ana Chacin	Co-Investigator	IRB_00104924	Interactive Multimedia Diversion Device with Breath Control	The investigator reports a significant financial interest in CKC Medical, who manufactures the device being studied.	no			yes	CKC Medical	Value cannot be readily determined	no	
CRV_00097703	Mark Yandell	Co-Investigator	IRB_00096551	The Familiality of Diabetes and Diabetes-Related Complications	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	yes	Fabric Genomics	\$80,000 to \$99,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00098426	Ben Chortkoff	Co-Investigator	IRB_00104924	Interactive Multimedia Diversion Device with Breath Control	The investigator reports a significant financial interest in CKC Medical, who manufactures the device being studied. The investigator's intellectual property is being used in this project. CKC Medical holds an option for the license on this technology.	no			yes	CKC Medical	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00098450	Scott Summers	Principal Investigator	10051304	TARGETING A CERAMIDE DOUBLE BOND TO TREAT CARDIOMETABOLIC DISORDERS	The investigator reports a significant financial interest in Centaurus Therapeutics, who will be providing novel inhibitors that will be used in this project.	yes	Centaurus Therapeutics	\$10,000 to \$19,999	yes	Centaurus Therapeutics	Value cannot be readily determined	no	
CRV_00098515	Marvin Moore	Key Personnel	IRB_00119139	Utah/Primary's Center for Pediatric Personalized Medicine (UP-cPPM)	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	yes	Fabric Genomics	\$20,000 to \$39,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)					Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00099149	Florian Solzbacher	Principal Investigator	10052265	DEVELOPMENT AND TRANSLATION OF SIC BASED ENCAPSULATION FOR CHRONIC NEURAL IMPLANTS IN A NOVEL AUDITORY NERVE IMPLANT	The investigator reports significant financial interests in Blackrock Microsystems, the sponsor of the project. The investigator's intellectual property will be involved in this project. The intellectual property is licensed to Blackrock Microsystems.	yes	Blackrock Microsystems	Over \$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00100565	Karen Eilbeck	Data Analyst	IRB_00100891	ENDOMETRIOSIS IMPRINTS (Infertility, Mortality (cancers), Pain, Reproductive outcomes (time to pregnancy, prematurity, preeclampsia, etc), Inheritance patterns (Is endometriosis one or multiple entities?), Noisome Traits (comorbidities) and Symptoms [IMP	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	yes	Omnicia	\$20,000 to \$39,999	yes	Omnicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00100578	Michael YU	Principal Investigator	10051759	IN SITU IMAGING OF COLLAGEN DEGRADATION ACTIVITY IN MULTIPLE MYELOMA AND LUNG FIBROSIS MURINE MODELS	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	no			yes	3Helix Inc	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00100732	Marvin Moore	Key Personnel	IRB_00125940	Personalized Pediatric Medicine (PPM) at the University of Utah	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$20,000 to \$39,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00100739	JASON SHEPHERD	Principal Investigator	10051280	VIRUS-LIKE INTERCELLULAR COMMUNICATION IN THE NERVOUS SYSTEM	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	no			yes	VNV Newcom	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00101451	ALANA WELM	Principal Investigator	10054932	PDX TRIAL CENTER FOR BREAST CANCER	The investigator's licensed intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00101453	Bryan Welm	Co-Investigator	10054932	PDX TRIAL CENTER FOR BREAST CANCER	The investigator's licensed intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00101754	Mark Yandell	Co-Investigator	10051171	PRIMARY OVARIAN INSUFFICIENCY: ETIOLOGY AND COMORBID DISEASE	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	yes	Omicia Inc (Fabric Genomics)	\$80,000 to \$99,999	yes	Omicia Inc (Fabric Genomics)	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00102072	Marvin Moore	Key Personnel	IRB_00126184	Genetic analysis of undiagnosed conditions	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	yes	Fabric Genomics	\$20,000 to \$39,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00102073	Mark Yandell	Co-Investigator	IRB_00126184	Genetic analysis of undiagnosed conditions	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	yes			yes			yes	Value cannot be readily determined
CRV_00103070	Karen Eilbeck	Principal Investigator	10036978	A Community Driven Framework for Genome Based Clinical Diagnostics	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	yes	Omnicia	\$80,000 to \$99,999	yes	Omnicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00105096	Rock Hadley	Co-Investigator	IRB_00114506	Validation of a Protocol for a Non-Invasive, Magnetic Resonance Guided Breast Cancer Therapy	The investigator's licensed intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00105378	James Hotaling	Co-Investigator	10053353	STREAM DX: POINT OF CARE CELLULAR ENABLED IOT COMMUNICATION HUB FOR IMPROVED DIAGNOSIS, MONITORING, AND POST-TREATMENT EVALUATION OF LUTS	The investigator's intellectual property is being evaluated in the study. The intellectual property has been exclusively licensed to StreamDX, a non-publicly traded company in which the investigator has significant equity interest.	no			yes	StreamDx	Value cannot be readily determined	yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)

Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00106192	Stephen Summers	Principal Investigator	10053353	STREAM DX: POINT OF CARE CELLULAR ENABLED IOT COMMUNICATION HUB FOR IMPROVED DIAGNOSIS, MONITORING, AND POST-TREATMENT EVALUATION OF LUTS	The investigator reports significant equity interest in StreamDx, whose device is being investigated in the study.	no			yes	Stream DX	Value cannot be readily determined	no	
CRV_00108069	Mark Yandell	Co-Investigator	IRB_00086989	A community driven framework for genome based clinical diagnostics.	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00108071	Karen Eilbeck	Co-Investigator	IRB_00086989	A community driven framework for genome based clinical diagnostics.	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00108828	Kenneth Aston	Co-Investigator	10055192	SPERM SAMPLE PREPARATION FOR POINT OF CARE APPLICATIONS	The investigator reports a significant financial interest in NanoNC, the sponsor of the project.	no			yes	Nanonc	Value cannot be readily determined	no	
CRV_00108830	James Hotaling	Co-Investigator	10055192	SPERM SAMPLE PREPARATION FOR POINT OF CARE APPLICATIONS	The investigator has a significant financial interest in NanoNC, the sponsor of the project. The investigator's intellectual property will be used in this project. This intellectual property is licensed by NanoNC.	no			yes	NanoNC	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00108865	Bingjian Feng	Co-Investigator	IRB_00062148	Head and neck cancer susceptibility genes	The investigator's intellectual property will be used in this project. The intellectual property is licensed to Ambry Genetics Corporation.	no			no			yes	Value cannot be readily determined
CRV_00109268	Martin McMahon	Co-Investigator	IRB_00129242	Elucidating the role of support signaling in promoting minimal residual disease in mouse models of oncogene-driven lung cancer.	The investigator reports his intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00109514	Philipp Taussky	Principal Investigator	10054260	A STUDY OF THE PIPELINE FLEX EMBOLIZATION DEVICE WITH SHIELD TECHNOLOGY FOR ENDOVASCULAR TREATMENT OF WIDE-NECKED INTRACRANIAL ANEURYSMS	The investigator reports a significant financial interest in Medtronic, the sponsor of the study.	yes	Medtronic	\$5,000 to \$9,999	no			no	
CRV_00109550	Anne Blaschke	Co-Investigator	10048481	ONGOING EVALUATION OF THE IMPACT OF THE INTRODUCTION OF PNEUMOCOCCAL CONJUGATE VACCINE (PCV-13) ON THE INCIDENCE OF PARAPNEUMONIC EMPYEMA AND OTHER INVASIVE PNEUMOCOCCAL DISEASE IN CHILDREN AND ADOLESCENTS IN ORANGE COUNTY, CALIFORNIA	The investigator reports a significant financial interest in BioFire Diagnostics, LLC. The investigator reports that her intellectual property will be used in this project.	yes	Biofire	\$5,000 to \$9,999	no			yes	Value cannot be readily determined
CRV_00109909	Kyle Turner	Principal Investigator	IRB_00129444	Relational Leadership Initiative: Assessing Implementation and Learning Outcomes of an Interprofessional, Cross-Generational Collaborative	The investigator reports a significant financial interest from Primary Care Progress, who provides program management services for the project.	yes	Primary Care Progress	\$10,000 to \$19,999	no			no	
CRV_00110507	ALISTAIR WARD	Data Analyst	IRB_00115011	University of Utah - Intermountain West Clinical Site for the Undiagnosed Disease Network (UDN)	The investigator has a significant financial interest in Frameshift Labs Inc., whose tool will be used in this project. The investigator's licensed intellectual property will be involved in the project. The intellectual property is licensed to Frameshift Labs.	yes	Frameshift Labs	Over \$100,000	yes	Frameshift Labs	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00110576	Martin McMahon	Principal Investigator	10046696	ELUCIDATING TUMOR PROGRESSION FACTORS IN MAPK-DRIVEN LUNG CANCERS	The investigator's licensed intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)					Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00110798	Robert Hitchcock	Principal Investigator	IRB_00082389	(MAP - Motherhood and Pelvic health) - Bridging physical and cultural determinants of postpartum pelvic floor support and symptoms following vaginal delivery	The investigator has a significant financial interest in Freyya, Inc, which will be involved in this project.	no			yes	Freyya inc	Value cannot be readily determined	no	
CRV_00111986	Mark Yandell	Principal Investigator	IRB_00108137	Rapid Sequencing in Acutely Ill Infants in the NICU	The investigator has a significant financial interest in Fabric Genomics, a company that creates tools that will be used in the analysis. The investigator's licensed intellectual property will be used in the project.	yes	Fabric Genomics	\$80,000 to \$99,999	yes	Fabric genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00111987	Mark Yandell	Principal Investigator	IRB_00125940	The Utah NeoSeq Project	The investigator has a significant financial interest in Fabric Genomics, a company that creates tools that will be used in the analysis. The investigator's licensed intellectual property will be used in the project.	yes	Fabric Genomics	\$80,000 to \$99,999	yes	Fabric Genomic	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00112451	Christopher Gregg	Co-Investigator	IRB_00130951	Behavioral Stories for Health	The investigator has a significant financial interest in Storyline Health, a company that manufactures a smartphone app that will be used in this study.	no			yes	Storyline Health	Value cannot be readily determined	no	
CRV_00113211	Jeremy Gililand	Co-Investigator	IRB_00128705	Trident II Acetabular Shell Revision Study	The investigator has a significant financial interest in Styker, the sponsor of the project.	yes	Stryker	\$10,000 to \$19,999	no			no	
CRV_00113309	Andrew Garrison	Co-Investigator	IRB_00130792	An educational intervention to address barriers to treating opioid use disorder at Community Health Centers, Inc, in Salt Lake City, UT.	The investigator has a significant financial interest in Community Health Centers, Inc., a company that will be involved in the study.	yes	Community Health Centers, Inc	Over \$100,000	no			no	
CRV_00114287	Christian Yost	Principal Investigator	IRB_00131977	NETosis in Human Respiratory Infection	The investigator's licensed intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00114451	Marvin Moore	Key Personnel	IRB_00108137	Rapid Sequencing in Acutely Ill Infants in the NICU	The investigator has a significant financial interest in Fabric Genomics, whose software will be involved in this project. The investigator's licensed intellectual property will be involved in the project. This intellectual property is licensed to Fabric Genomics.	yes	Fabric Genomics	\$20,000 to \$39,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00115152	Lisa Gren	Co-Investigator	IRB_00091063	Evaluating the Impact of a Mind-Body Bridging Intervention with Firefighters in Salt Lake City	The investigator's licensed intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00115340	Christopher Peters	Co-Investigator	10032753	A Clinical Evaluation of the Vanguard XP Bicruciate Knee System Early Intraoperative & Candidacy Assessment	The investigator's licensed intellectual property will be evaluated in the research.	no			no			yes	Value cannot be readily determined
CRV_00115357	Christopher Peters	Co-Investigator	IRB_00096272	Outcomes following total joint arthroplasty of the hip or knee using Zimmer Biomet Implants.	The investigator's licensed intellectual property will be evaluated in the research	no			no			yes	Value cannot be readily determined
CRV_00115358	Christopher Peters	Co-Investigator	IRB_00089804	Evaluation of serum metal ion levels in a series of patients undergoing primary or revision total hip arthroplasty with the G7 Dual Mobility Construct	The investigator's licensed intellectual property will be evaluated in the research.	no			no			yes	Value cannot be readily determined
CRV_00115360	Christopher Peters	Co-Investigator	IRB_00075446	Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty	The investigator's licensed intellectual property will be evaluated in the research.	no			no			yes	Value cannot be readily determined
CRV_00115368	Christopher Peters	Co-Investigator	IRB_00062862	Vanguard SSK 360 Revision Knee System Global Data Collection	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)					Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00115496	Mark Yandell	Co-Investigator	IRB_00133041	Artificial intelligence to explore the role of blood pressure in outcomes among patients with atrial fibrillation	The investigator has a significant financial interest in Backdrop Health Inc. The investigator's licensed intellectual property will be used in the project. The investigator's intellectual property is licensed to Backdrop Health Inc.	no			yes	Backdrop Health Inc.	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00116290	Christian Yost	Principal Investigator	IRB_00011919	NETs: Protection or Harm in Neonatal Inflammation or Infection	The investigator's licensed intellectual property will be involved in the project.	no			no			yes	Value cannot be readily determined
CRV_00117509	Massood Tabib-Azar	Principal Investigator	IRB_00134267	COVID-19 Sensors	The investigator reports several intellectual properties that are imminent of commercialization will be used in the study. The investigator has a significant financial interest in Utah Wireless Health Sensors, the company interested in licensing the technologies.	no			no			yes	Value cannot be readily determined
CRV_00117562	Mark Yandell	Co-Investigator	10053650	A NOVEL ROLE FOR NFATC1 IN MODULATING CARDIAC EXCITABILITY	The investigator's licensed intellectual property will be used in the project. The intellectual property is licensed to Fabric Genomics, a company in which the investigator has a significant financial interest.	no			no			yes	Value cannot be readily determined
CRV_00118159	Christopher Gregg	Co-Investigator	IRB_00131657	COVID-19 & the Effect of Social Isolation on Health	The investigator has a significant financial relationship with Storyline Health, a company that will be involved in the research.	no			yes	Storyline Health	Value cannot be readily determined	no	
CRV_00118187	Alexander Henrie	Data Analyst	IRB_00017613	Familial kinship analysis in patients with Mullerian anomalies	The investigator has a significant financial interest in Backdrop Health Inc. Backdrop developed software that will be used in this study.	no			yes	Backdrop Health Inc	Value cannot be readily determined	no	
CRV_00118326	Martin McMahon	Principal Investigator	10054977	ELUCIDATING THE ROLE OF PI3K LIPID EFFECTORS IN BRAF MUTANT MELANOMA	The investigator's licensed intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00118414	Massood Tabib-Azar	Principal Investigator	IRB_00134736	Point-of-care Sensors to detect COVID-19	The investigator reports their intellectual property will be involved in this project. The investigator reports these properties are currently being licensed to Utah Wireless Health Sensors, LLC. The Investigator reports significant financial interest in Utah Wireless Health Sensors, LLC.	yes	Utah Wireless Health Sensors	\$10,000 to \$19,999	yes	Utah Wireless Health Sensors	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00118625	Kensaku Kawamoto	Principal Investigator	IRB_00134238	Design, Implementation and Evaluation of Scalable Decision Support for Diabetes Care	The investigator's licensed intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00118905	Philipp Taussky	Principal Investigator	IRB_00124567	COVSHLD0569 (ADVANCE): A Study of the Pipeline™ Vantage Embolization DeVice with Shield Technology™ for Endovascular Treatment of Wide-Necked Intracranial Aneurysms	The investigator has a significant financial interest in Medtronic, Inc., the sponsor of the study.	yes	Medtronic INC	\$10,000 to \$19,999	no			no	
CRV_00121031	Jayant Agarwal	Principal Investigator	10056694	A NOVEL BIODEGRADABLE NERVE CONDUIT DRUG DELIVERY DEVICE FOR PERIPHERAL NERVE REPAIR	The investigator has a significant financial interest in Microsurgical Innovations, the sponsor of the study.	no			yes	Microsurgical Innovations	Value cannot be readily determined	no	

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)

Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00121119	Florian Solzbacher	Principal Investigator	10055936	DEVELOPMENT OF A HIGH (60) CHANNEL NEUROSTIMULATOR FOR AN AUDITORY NERVE IMPLANT	The investigator has significant financial interests (remuneration and equity) in Blackrock Microsystems, the sponsor of the project. The investigator's licensed intellectual properties will be directly involved in the project. These intellectual properties are licensed to Blackrock Microsystems.	yes	Blackrock Microsystems	Over \$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00121857	Gabor Marth	Principal Investigator	10055226	CARDIOVASCULAR DEVELOPMENTAL BIOLOGY DATA RESOURCE CENTER (CDDRC)	The investigator has a significant financial interest in Frameshift Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.	no			yes	Frameshift Labs	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00123008	Kerry Kelly	Principal Investigator	10054853	SCC-IRG TRACK 2: SMART AIR: INFORMING DRIVING BEHAVIOR THROUGH DYNAMIC AIR-QUALITY SENSING AND SMART MESSAGING	The investigator reports that the technology developed from this project may be commercialized by Tetrad: Sensor Network Solutions, LLC.	no			yes	Tetrad: Sensor Network Solutions, LLC	Value cannot be readily determined	no	
CRV_00123124	Alexander Henrie	Data Analyst	IRB_00100891	ENDOMETRIOSIS IMPRINTS (Infertility, Mortality (cancers), Pain, Reproductive outcomes (time to pregnancy, prematurity, preeclampsia, etc), Inheritance patterns (Is endometriosis one or multiple entities?), Noisome Traits (comorbidities) and Symptoms (IMP	The investigator has a significant financial interest in Backdrop Health Inc, who are in the process of commercializing the software that will be used in this project.	no			yes	Backdrop Health Inc	Value cannot be readily determined	no	
CRV_00123486	BENJAMIN SANCHEZ TERRONES	Principal Investigator	10058386	IMPROVING ALS DIAGNOSIS USING NEEDLE I-EMG	The investigator has a significant financial interest in Haystack Diagnostics, Inc., the sponsor of the project.	no			yes	Haystack Diagnostics, Inc.	Value cannot be readily determined	no	
CRV_00124108	Safdar Ansari	Principal Investigator	IRB_00125830	StrokeNet cIRB Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery (ASPIRE)	The investigator has a significant financial interest in Pfizer. The study drug, Apixaban, was co-developed by Pfizer.	yes	Pfizer	\$5,000 to \$9,999	no			no	
CRV_00125426	Richard Landward	Co-Investigator	IRB_00105159	Training physical therapist to support patient self-management of chronic musculoskeletal conditions.	The investigator's licensed intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00125946	Jill Shea	Co-Investigator	10056694	A NOVEL BIODEGRADABLE NERVE CONDUIT DRUG DELIVERY DEVICE FOR PERIPHERAL NERVE REPAIR	The investigator's licensed intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00126641	Shaun Mendenhall	Principal Investigator	IRB_00133012	Patient outcomes following upper and lower extremity reconstruction	The investigator has a significant financial interest (remuneration) in PolyNovo. PolyNovo's product will be evaluated in the study.	yes	PolyNovo	\$5,000 to \$9,999	no			no	
CRV_00127944	Kensaku Kawamoto	Co-Investigator	IRB_00137874	The Use of Non-Interruptive Alerts for Improving the Use of Clinical Decision Rules in the Emergency Department: A Cluster Randomized Controlled Trial	The investigator's licensed intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00127946	Phillip Warner	Key Personnel	IRB_00137874	The Use of Non-Interruptive Alerts for Improving the Use of Clinical Decision Rules in the Emergency Department: A Cluster Randomized Controlled Trial	The investigator's licensed intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00127980	Debra Eckert	Co-Investigator	IRB_00054476	D-peptide Inhibitors of HIV-1 Entry	The investigator reports their intellectual property will be involved in this project. The property is licensed to Navigen, a company in which the the investigator has a significant financial interest.	no			yes	Navigen	Value cannot be readily determined	yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)

Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00128069	Kyle Turner	Principal Investigator	IRB_00134146	Healthcare workforce experiences with relational leadership programming through the lens of self-determination theory	The investigator has a significant financial interest (remuneration) in Primary Care Progress, a company that will be involved in the project.	yes	Primary Care Progress	\$5,000 to \$9,999	no			no	
CRV_00128201	Diane Tyler	Research Coordinator	IRB_00072802	Contextual Delivery of Medical Alarms	The investigator has a significant financial interest (remuneration) in Applied Medical Visualizations LLC., whose products will be evaluated in the research.	yes	Applied Medical Visualizations LLC	\$5,000 to \$9,999	no			no	
CRV_00128310	Joshua Schiffman	Co-Investigator	IRB_00136729	Childhood Cancer Predisposition Study	The investigator has significant financial interests (equity interest) in ItRunsInMyFamily. The company's product will be used in the study.	no			yes	ItRunsInMyFamily.com	Value cannot be readily determined	no	
CRV_00128575	Edward Dudek	Principal Investigator	10058182	NIH/MGH R33: ANTICONVULSANT SCREENING USING CHRONIC EPILEPSY MODELS	The investigator's licensed intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00128789	Burt Richards	Co-Investigator	IRB_00010201	Genetic and Molecular Studies Of Eye Diseases	The investigator reports a significant financial interest (licensed intellectual property) that will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00128966	Brad Lundahl	Co-Investigator	IRB_00105159	Training physical therapist to support patient self-management of chronic musculoskeletal conditions.	The investigator has a significant financial interest (equity) in Testudos or Esympro, a non-publicly traded company whose products will be evaluated in the research.	no			yes	Testudos or Esympro with Brian and Cassia Connors	Value cannot be readily determined	no	
CRV_00129601	Mark Yandell	Principal Investigator	10055224	BRIDGING THE GAP BETWEEN GENOMICS AND CLINICAL OUTCOMES IN CHD	The investigator's licensed intellectual properties will be involved in this project. These technologies are licensed to Backdrop Health, IDbyDNA, and Fabric Genomics. The investigator has a significant financial interest in Fabric Genomics, IDbyDNA, and Backdrop Health.	yes	IDbyDNA Inc; Fabric Genomics	\$60,001 to \$79,999; \$80,000 to \$99,999	yes	Fabric Genomics; IDbyDNA Inc; Backdrop Health	Value cannot be readily determined Value cannot be readily determined Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00130945	Jeffrey Rosenbluth	Key Personnel	IRB_00093707	Control Preference for Spinal Cord Injury Patients in a Skiing and Sailing Game	The investigator's licensed intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00130946	Jeffrey Rosenbluth	Key Personnel	IRB_00064736	Community-based health interventions: Decreasing secondary conditions associated with spinal cord injury	The investigator's licensed intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00131099	Alexander Henrie	Data Analyst	IRB_00125940	The Utah NeoSeq Project	The investigator has a significant financial interest in Backdrop Health Inc., a non-publicly traded company. Software owned by Backdrop Health will be used in this project.	no			yes	Backdrop Health	Value cannot be readily determined	no	
CRV_00131179	Philipp Taussky	Co-Investigator	IRB_00136326	Embolization of the Middle Meningeal Artery with ONYX™ Liquid Embolic System In the Treatment of Subacute and Chronic Subdural Hematoma (EMBOLISE)	The investigator has a significant financial interest (remuneration) in Medtronic, the sponsor of the study.	yes	Medtronic	\$10,000 to \$19,999	no			no	
CRV_00131190	Alexander Henrie	Data Analyst	IRB_00021614	Endometriosis: Natural History, Diagnosis, and Outcomes (ENDO)	The investigator has a significant financial interest in Backdrop Health Inc. Software being commercialized by Backdrop will be used in this project.	no			yes	Backdrop Health	Value cannot be readily determined	no	
CRV_00131193	Alexander Henrie	Data Analyst	IRB_00006042	Genetics Of Autism	The investigator has a significant financial interest in Backdrop Health Inc, a non-publicly traded company whose software may be used in the study.	no			yes	Backdrop Health	Value cannot be readily determined	no	
CRV_00131368	Josh Bonkowsky	Principal Investigator	10058507	SYSTEMS FOR RAPID GENERATION OF ZEBRAFISH MUTANTS AND ZEBRAFISH EMBRYO HANDLING	The investigator has intellectual property that will be used in this research. The technology is licensed to wFluidx, a company in which the investigator has a significant financial interest.	no			yes	wFluidx	Value cannot be readily determined	yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)					Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00132830	Christian Yost	Co-Investigator	IRB_00139857	Regulation of neutrophil extracellular traps and NET-inhibitory factors in ARDS	The investigator's licensed intellectual property will be used in the study. The intellectual property is licensed to Peel Therapeutics, Inc.	no			no			yes	Value cannot be readily determined
CRV_00133932	Lisa Gren	Principal Investigator	IRB_00139652	MindShield	The investigator reports their intellectual property will be involved in this project. This technology is licensed to True North Behavioral Health.	no			no			yes	Value cannot be readily determined
CRV_00134746	Alexander Becraft	Principal Investigator	IRB_00140200	Mental Health Prevention and Promotion: Leveraging positive psychological interventions and social entrepreneurship to build resilience and well-being in college students	The investigator has a significant financial interest in Wellbeing Elevated, Inc. Wellbeing Elevated's intellectual property will be evaluated in the study.	yes	Wellbeing Elevated, Inc.	\$10,000 to \$19,999	yes	Wellbeing Elevated, Inc.	Value cannot be readily determined	no	
CRV_00134917	Gordon Lemmon	Data Analyst	IRB_00136167	EXEMPTION UMBRELLA: Assembling de-identified machine learning datasets for outcomes research.	The investigator reports a significant financial interest (equity) in Backdrop Health, a non-publicly traded company. Technology owned by Backdrop will be used in this project.	no			yes	Backdrop Health	Value cannot be readily determined	no	
CRV_00134918	Gordon Lemmon	Data Analyst	IRB_00021614	Endometriosis: Natural History, Diagnosis, and Outcomes (ENDO)	The investigator reports a significant financial interest (equity) in Backdrop Health, a non-publicly traded company. Technology owned by Backdrop will be used in this project.	no			yes	Backdrop Health	Value cannot be readily determined	no	
CRV_00134920	Gordon Lemmon	Data Analyst	IRB_00067518	Retrospective study of prognostic and predictive factors in advanced urologic cancers	The investigator reports a significant financial interest (equity) in Backdrop Health, a non-publicly traded company. Technology owned by Backdrop will be used in this project.	no			yes	Backdrop Health	Value cannot be readily determined	no	
CRV_00134922	Gordon Lemmon	Data Analyst	IRB_00095807	A Pilot Study of Discovery-Driven Big Data Science: Empowering Evidence-Based Research to Improve the Value of Pediatric Cardiovascular Care	The investigator reports a significant financial interest (equity) in Backdrop Health, a non-publicly traded company. Technology owned by Backdrop will be used in this project.	no			yes	Backdrop Health	Value cannot be readily determined	no	
CRV_00134923	Gordon Lemmon	Data Analyst	IRB_00017613	Familial kinship analysis in patients with Mullerian anomalies	The investigator reports a significant financial interest (equity) in Backdrop Health, a non-publicly traded company. Technology owned by Backdrop will be used in this project.	no			yes	Backdrop Health	Value cannot be readily determined	no	
CRV_00134924	Gordon Lemmon	Data Analyst	IRB_00006042	Genetics Of Autism	The investigator has a significant financial interest (equity) in Backdrop Health Inc.	no			yes	Backdrop Health	Value cannot be readily determined	no	
CRV_00134925	Gordon Lemmon	Data Analyst	IRB_00013791	Utah Infertility Registry- Polycystic Ovary Syndrome (UIR-PCOS)	The investigator reports a significant financial interest (equity) in Backdrop Health, a non-publicly traded company. Technology owned by Backdrop will be used in this project.	no			yes	Backdrop Health	Value cannot be readily determined	no	
CRV_00135422	Jeremy Gililand	Co-Investigator	10057465	TRIDENT II ACETABULAR SHELL REVISION STUDY	The investigator reports a significant financial interest (remuneration) from Styker, the sponsor of the project.	yes	Stryker	\$10,000 to \$19,999	no			no	
CRV_00136439	Christopher Gregg	Key Personnel	IRB_00135711	Behavioral micro-features in treatment-resistant mood disorders	The investigator reports a significant financial interest (equity) in Storyline Health.	no			yes	Storyline Health	Value cannot be readily determined	no	
CRV_00137071	Paul Bernstein	Principal Investigator	10059603	TESSERACT IC COMPARISON STUDY OF OPTICAL COHERENCE TOMOGRAPHY, FUNDUS AND FUNDUS AUTOFLUORESCENCE IMAGES TO THE PREDICATE DEVICES	The investigator reports significant financial interest (remuneration) from the sponsor of the study, Tesseract.	yes	Tesseract Health	\$5,000 to \$9,999	no			no	

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)

Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00138558	Marvin Moore	Key Personnel	IRB_00035848	GENETIC ANALYSIS OF CONGENITAL DIAPHRAGMATIC DISORDERS	The investigator reports a significant financial interest in Fabric Genomics, a non-publicly traded company which licenses the intellectual property for commercial applications.	yes	Fabric Genomics	\$20,000 to \$39,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00140105	Stacey Clardy	Co-Investigator	IRB_00141212	Neurology Podcast “Journal Club” Assessment Survey	The investigator reports significant financial interest (remuneration) from American Academy of Neurology. The Podcast is a product of AAN via its journal.	yes	American Academy of Neurology	\$10,000 to \$19,999	no			no	
CRV_00140131	JAN PIERCE	Co-Investigator	10058271	A PHASE I/II RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED CLINICAL TRIAL TO DETERMINE SAFETY AND FEASIBILITY OF USING ACELLULAR STERILE FILTERED AMNIOTIC FLUID AS A TREATMENT FOR COVID-19 PATIENTS	The investigator's intellectual property is being used in the study. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.	yes	Eliksa	\$10,000 to \$19,999	yes	Eliksa	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00140132	JAN PIERCE	Co-Investigator	IRB_00132922	A Phase I/II Randomized Double-Blinded Placebo-Controlled Clinical Trial to Determine Safety and Feasibility of Using an Acellular Sterile Filtered Amniotic Fluid as a Treatment for COVID-19 Patients	The investigator's intellectual property is being used in the study. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.	yes	Eliksa	\$10,000 to \$19,999	yes	Eliksa	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00140135	JAN PIERCE	Co-Investigator	IRB_00099569	A Phase I/II Randomized, Double-Masked, Placebo-Controlled Study for determining the safety of processed Amniotic Fluid (pAF) Drops after Photorefractive Keratectomy	The investigator's intellectual property is being used in the study. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.	yes	Eliksa	\$10,000 to \$19,999	yes	Eliksa	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00140137	JAN PIERCE	Co-Investigator	IRB_00128708	A Phase I/II Clinical Trial to Determine Safety and Feasibility of Using an Acellular Amniotic Fluid Application to Expedite Healing in Chronic Wounds (pAF for Chronic Wounds)	The investigator's intellectual property is being used in the study. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.	yes	Eliksa	\$10,000 to \$19,999	yes	Eliksa	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00140138	JAN PIERCE	Co-Investigator	IRB_00103515	A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY FOR THE TREATMENT OF OCULAR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) WITH PROCESSED AMNIOTIC FLUID (pAF) DROPS	The investigator's intellectual property is being used in the study. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.	yes	Eliksa	Zero to \$4,999	yes	Eliksa	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00140154	John Phillips	Co-Investigator	IRB_00132922	A Phase I/II Randomized Double-Blinded Placebo-Controlled Clinical Trial to Determine Safety and Feasibility of Using an Acellular Sterile Filtered Amniotic Fluid as a Treatment for COVID-19 Patients	The investigator's intellectual property is being used in the study. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.	yes	Eliksa	Zero to \$4,999	yes	Eliksa	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00140159	John Phillips	Co-Investigator	IRB_00128708	A Phase I/II Clinical Trial to Determine Safety and Feasibility of Using an Acellular Amniotic Fluid Application to Expedite Healing in Chronic Wounds (pAF for Chronic Wounds)	The investigator's intellectual property is being used in the study. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.	yes	Eliksa	Zero to \$4,999	yes	Eliksa	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00140160	John Phillips	Principal Investigator	IRB_00103515	A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY FOR THE TREATMENT OF OCULAR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) WITH PROCESSED AMNIOTIC FLUID (pAF) DROPS	The investigator's intellectual property is being used in the study. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.	yes	Eliksa	Zero to \$4,999	yes	Eliksa	Value cannot be readily determined	yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)

Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00140405	Eric Garland	Principal Investigator	IRB_00141495	Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder	The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR. BehaVR licensed the therapy developed.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00140409	Eric Garland	Principal Investigator	10061010	FROELIGER NICOTINE R01 SUB: NEURAL MECHANISMS MEDIATING APPETITIVE REGULATION AND SMOKING IN NICOTINE ADDICTION	The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00140418	Eric Garland	Principal Investigator	10050111	MUSC R01 NEURAL MECHANISMS MEDIATING APPETITIVE REGULATION AND SMOKING IN NICOTINE ADDICTION SUBAWARD	The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00140419	Eric Garland	Principal Investigator	10040208	Targeting Hedonic Dysregulation in Chronic Pain and Opioid Misuse with Mindfulness-Oriented Recovery Enhancement: A RCT in Primary Care	The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00140420	Eric Garland	Principal Investigator	10040437	Targeting Chronic Pain and Co-Occurring Disorders in the Community with Mindfulness-Oriented Recovery Enhancement	The investigator's intellectual property will be used in the study. The investigator reports a significant financial interest (remuneration) from BehaVR, who has licensed the intellectual property.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00140426	Eric Garland	Co-Investigator	10045550	SMART Stepped Care Management for Low Back Pain in Military Health System	The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00140444	Eric Garland	Principal Investigator	IRB_00129302	Near-infrared spectroscopy-based neurofeedback as adjunct to Mindfulness-Oriented Recovery Enhancement in persons with chronic pain.	The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00140448	Eric Garland	Co-Investigator	IRB_00116150	SMART LBP: Optimized Multidisciplinary Treatment Programs for Nonspecific Chronic Low Back Pain	The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00140817	JAN PIERCE	Co-Investigator	IRB_00128491	A Phase I/II Randomized Double-Blinded Standard of Care (Corticosteroid) vs. Sterile Amniotic Fluid for Osteoarthritis	The investigator's intellectual property is being used in the study. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.	yes	Eliksa	\$10,000 to \$19,999	yes	Eliksa	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00140818	John Phillips	Co-Investigator	IRB_00128491	A Phase I/II Randomized Double-Blinded Standard of Care (Corticosteroid) vs. Sterile Amniotic Fluid for Osteoarthritis	The investigator's intellectual property is being used in the study. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.	yes	Eliksa	Zero to \$4,999	yes	Eliksa	Value cannot be readily determined	yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)

Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00140825	JAN PIERCE	Co-Investigator	IRB_00131761	A Phase I/II Double-Blinded Randomized Prospective Study of Sterile Amniotic Fluid Filtrate Epidural Injection for the treatment of Lumbosacral Radicular Pain due to Spinal Stenosis: The SAFE Trial (Improving Safety and Outcomes in the Treatment of Pain	The investigator's intellectual property is being used in the study. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.	yes	Eliksa	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00140980	Philipp Taussky	Principal Investigator	10054308	AN ENDOVASCULAR EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE EVOLVE FLOW-DIVVERTER SYSTEM USED IN THE TREATMENT OF SMALL WIDE-NECK INTRACRANIAL ANEURYSMS (EVOLVE)	The investigator reports significant financial interest (remuneration) in Stryker, the sponsor of the project.	yes	Stryker	\$5,000 to \$9,999	no			no	
CRV_00141458	Eric Garland	Co-Investigator	IRB_00141097	Enriched Pain Management for Lumbar Spine Surgery	The investigator reports significant financial interest from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00142323	ALISTAIR WARD	Data Analyst	IRB_00084861	PEDIATRIC CARDIAC GENOMICS CONSORTIUM: CONGENITAL HEART DISEASE GENETIC NETWORK STUDY (CHD GENES)	The investigator reports significant financial interest (remuneration and equity) in Frameshift Labs Inc., which is developing the software being examined in this project.	yes	Frameshift Labs	Over \$100,000	yes	Frameshift Labs	Value cannot be readily determined	no	
CRV_00143053	Luke Maese	Co-Investigator	IRB_00127782	AALL1931/JZP458-201 An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. coli-derived Asparaginases	The investigator has a significant financial interest (remuneration) in Jazz Therapeutics, the study sponsor.	yes	Jazz Therapeutics	\$5,000 to \$9,999	no			no	
CRV_00143304	Stephanie Klein	Principal Investigator	10059643	THE EFFECT OF GLYCOPYRRONIUM CLOTHS ON AMPUTATION SITE HYPERHIDROSIS	The investigator reports significant financial interest (remuneration) from the study sponsor, Dermira Inc. a publicly traded company.	yes	Dermira, Inc	\$5,000 to \$9,999	no			no	
CRV_00143734	Mark Yandell	Co-Investigator	10057983	GENETIC AND FUNCTIONAL ANALYSIS OF RAPID RENAL DECLINE IN DIABETES: A FAMILY-BASED APPROACH TO ACCELERATE GENE DISCOVERY	The investigator reports significant financial interest from Backdrop Health Inc. and Fabric Genomics. The investigator's intellectual property licensed to Backdrop Health Inc. and Fabric Genomics (both non-publicly traded) will be used in the study.	yes	Fabric Genomics	\$80,000 to \$99,999	yes	Fabric Genomics; Backdrop Health Inc.	Value cannot be readily determined Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00143831	Kathryn Peterson	Principal Investigator	10051739	A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS	The investigator reports significant financial interest (remuneration) from the study sponsor Regeneron, a publicly traded company.	yes	REGENERON PHARMACEUTICALS INC	\$5,000 to \$9,999	no			no	
CRV_00143861	Kathryn Peterson	Co-Investigator	IRB_00031215	Genetic and Molecular Characteristics of Interstitial Lung Disease	The investigator reports significant financial interest (remuneration) from the sponsor of the study, Regeneron Pharmaceuticals Inc., a publicly traded company.	yes	Regeneron Pharmaceuticals Inc.	\$5,000 to \$9,999	no			no	
CRV_00143863	Kathryn Peterson	Principal Investigator	IRB_00120211	Regeneron R668-EE-1774: A Phase 3, Randomized, 3-Part Study To Investigate The Efficacy And Safety Of Dupilumab In Adult And Adolescent Patients With Eosinophilic Esophagitis.	The investigator reports significant financial interest (remuneration) from the study sponsor, Regeneron, a publicly traded company.	yes	REGENERON	\$5,000 to \$9,999	no			no	
CRV_00144851	Ravi Ranjan	Co-Investigator	IRB_00137228	LEADLESS II - A safety and effectiveness trial for a leadless pacemaker system	The investigator reports significant financial interest from the sponsor of the study, Abbott Laboratories.	yes	Abbott Laboratories	\$5,000 to \$9,999	no			no	

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)

Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00145246	Kerry Kelly	Co-Investigator	10060076	A MULTICITY STUDY OF WINTERTIME INVERSIONS AND ACUTE CARDIORESPIRATORY HEALTH EVENTS IN THE WESTERN U.S.	The investigator reports significant financial interest (equity) in Tetrad: Sensor Network Solutions, LLC (a non-publicly traded company). The study will be collecting publicly available data from the Tetrad website.	no			yes	Tetrad: Sensor Network Solutions, LLC	Value cannot be readily determined	no	
CRV_00145593	Jeremy Gililand	Co-Investigator	IRB_00143682	Long term follow-up of Trident II Acetabular Shell	The investigator reports significant remuneration in Stryker, the manufacturer of Trident II acetabular component being used in the study.	yes	Stryker	\$10,000 to \$19,999	no			no	
CRV_00145848	Luke Maese	Co-Investigator	10060522	COG STUDY: AAML1831: A COLLABORATION BETWEEN COG, JAZZ PHARMACEUTICALS, ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC., AND FOUNDATION MEDICINE, INC.	The investigator reports significant financial interest (remuneration) from Jazz Pharmaceuticals, one of the collaborators in the study.	yes	Jazz Pharmaceuticals	\$5,000 to \$9,999	no			no	
CRV_00145942	Stephanie Klein	Principal Investigator	IRB_00139912	A Prospective Trial to Assess how Glycopyrronium Cloths at the Amputation Site of Limb Amputees Changes the Severity of Hyperhidrosis and the Fit and Function of the Prosthetic Measured by Patient Reported Outcomes	The investigator reports significant financial interest (remuneration) from the manufacturer of the main product in the study, Dermira Inc. a publicly traded company.	yes	Dermira, Inc.	\$5,000 to \$9,999	no			no	
CRV_00146311	Eric Garland	Principal Investigator	IRB_00091781	Behavioral interventions for active duty service members and veterans with chronic pain conditions and opioid related problems	The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00146689	Luke Maese	Co-Investigator	IRB_00134143	CIRB AAML1831 A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations	The investigator reports significant financial interest (remuneration) from Jazz Pharmaceuticals, one of the collaborators in the study.	yes	Jazz Pharmaceuticals	\$5,000 to \$9,999	no			no	
CRV_00146694	Zachary Imel	Principal Investigator	IRB_00144605	Implementation of Technology-Based Evaluation of Motivational Interviewing	The investigators intellectual property is being used in the study. This technology is licensed to Lyssn.io, a non-publicly traded company in which the investigator reports a significant financial interest.	yes	Lyssn.io	\$10,000 to \$19,999	yes	Lyssn.io	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00146928	Andrew Zayachkivsky	Co-Investigator	10058182	NIH/MGH R33: ANTICONVULSANT SCREENING USING CHRONIC EPILEPSY MODELS	The investigator's intellectual property is used in this project. This technology is licensed to BIOPAC, a non-publicly traded company in which the investigator has a significant financial interest.	yes	BIOPAC	\$5,000 to \$9,999	no			yes	Value cannot be readily determined
CRV_00147619	Eric Garland	Principal Investigator	IRB_00078615	Behavioral Interventions for Chronic Pain and Opioid Related Problems	The investigator's intellectual property will be used in the study. This technology is licensed to BehaVR, a non-publicly traded company in which the investigator has a significant financial interest.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00148355	Eric Garland	Co-Investigator	10058817	BEHAVR R43/R44 SUBAWARD	The investigator's intellectual property will be used in the study. This technology is licensed to BehaVR, a non-publicly traded company in which the investigator has a significant financial interest.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)						Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest							
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00148382	Eric Garland	Principal Investigator	IRB_00130630	Mindfulness Oriented Recovery Enhancement (MORE) with Ketamine Assisted Psychotherapy (KAP) for the Treatment of Opioid Use Disorder	The investigator's intellectual property will be used in the study. This technology is licensed to BehaVR, a non-publicly traded company in which the investigator has a significant financial interest.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00148479	Roger Freedman	Co-Investigator	IRB_00137228	LEADLESS II - A safety and effectiveness trial for a leadless pacemaker system	The investigator reports significant financial interest (remuneration) from the sponsor of the study, Abbott Laboratories.	yes	Abbott Laboratories	\$5,000 to \$9,999	no			no	
CRV_00148671	Mary Scholand	Principal Investigator	IRB_00143600	RIN-PF-301 (TETON): A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis	The investigator reports significant financial interest with United Therapeutics, the study sponsor.	yes	United Therapeutics	\$5,000 to \$9,999	no			no	
CRV_00149124	Allison Payne	Principal Investigator	IRB_00145008	Developing a tissue viability imaging biomarker for use in non-invasive breast cancer therapy	The investigator reports their licensed intellectual property will be involved in this project.	no			no			yes	Value cannot be readily determined
CRV_00149152	Philipp Taussky	Principal Investigator	IRB_00131046	EVOLVE: EndoVascular Treatment Of Wide-Neck Aneurysms, an Evaluation of Safety and Effectiveness of Stryker Surpass valve™ Flow Diverter System	The investigator reports significant financial interest from the sponsor of the study, Stryker Neurovascular.	yes	Stryker Neurovascular	\$5,000 to \$9,999	no			no	
CRV_00149211	David Warren	Key Personnel	10061070	INTELLIGENT NEURAL INTERFACES EXPERIMENTAL FOLLOW-ON	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00149288	BENJAMIN SANCHEZ TERRONES	Co-Investigator	IRB_00145489	Development and Human Testing of an Impedance-Electromyography System for the Diagnosis of Muscular Disorders. HAYSTACK	The investigator reports significant financial interest (equity interest) and licensed intellectual property in Haystack Diagnostics, Inc. a non-publicly traded company, the sponsor of the study.	no			yes	Haystack Diagnostics, Inc.	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00149821	Florian Solzbacher	Co-Investigator	10059510	ENGINEERING A TRANSITION MICRO-ELECTRODE ARRAY FOR LARGE-SCALE BRAIN RECORDING AND MODULATION	The investigator reports significant financial interest (remuneration and equity) in Blackrock Microsystems Europe GmbH and Blackrock Microsystems. The company is commercializing neural interface electrodes and licensing technologies from the University.	yes	Blackrock Microsystems	Over \$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	no	
CRV_00149998	Bruce Gale	Principal Investigator	10058507	SYSTEMS FOR RAPID GENERATION OF ZEBRAFISH MUTANTS AND ZEBRAFISH EMBRYO HANDLING	The investigator reports a significant financial interest with wFluidx, who has licensed the investigator's intellectual property being used in the study, and a significant financial interest with the study sponsor Advanced Conceptions (formerly NanoNC).	yes	Advanced Conceptions	\$5,000 to \$9,999	yes	Advanced Conceptions	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00150013	Bruce Gale	Co-Investigator	IRB_00093004	Study of microfluidics cell sperm separation and storage technology development.	The investigator has significant financial interest in Advanced Conceptions (formerly NanoNC), which is interested in licensing the intellectual property being evaluated in the study.	yes	Advanced Conceptions	\$5,000 to \$9,999	yes	Advanced Conceptions	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00150162	Christopher Gregg	Co-Investigator	IRB_00143135	Precision Behavioral Oncology - Deep AI Behavioral Profiling to Reveal Mental and Behavioral Phenotypes Shaping Cancer Outcomes	The investigator reports significant financial interest in Storyline Health, which provides the artificial intelligence platform being used in the study to build models of cancer patient care.	no			yes	Storyline Health	Value cannot be readily determined	no	
CRV_00150227	Kent Lai	Principal Investigator	10055108	MRNA THERAPY FOR CLASSIC GALACTOSEMIA	The investigator's intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00150455	Derek Dosdall	Principal Investigator	10059746	ANTITACHYCARDIA PACING AND IMPROVED LEAD FOR VENTRICULAR CONDUCTION SYSTEM STIMULATION	The investigator's intellectual property will be used in the study.	no			no			yes	

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)						Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest							
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00151989	Eric Garland	Co-Investigator	IRB_00147100	A single-session of Mindfulness Oriented Recovery Enhancement for pain and distress	The investigator's intellectual property will be used in the study. This technology is licensed to BehaVR, a non-publicly traded company in which the investigator has a significant financial interest.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00152018	Julia Batten	Co-Investigator	IRB_00130937	Seagen SGN22E-003 >> An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer	The investigator reports significant financial interest with Seagen, who sponsors the study and manufactures enfortumab vedotin.	yes	Seagen (Seattle Genetics Inc.)	\$5,000 to \$9,999	no			no	
CRV_00152245	Florian Solzbacher	Principal Investigator	10063055	DEVELOPMENT OF A HIGH (60) CHANNEL NEUROSTIMULATOR FOR AN AUDITORY NERVE IMPLANT	The investigator's intellectual property will be used in the study. The investigator reports a significant financial interest in Blackrock Microsystems, the study sponsor.	yes	Blackrock Microsystems	Over \$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00154868	Jayant Agarwal	Principal Investigator	10056694	A novel biodegradable nerve conduit drug delivery device for peripheral nerve repair	The investigator reports significant financial interest in Microsurgical Innovations, the sponsor of the study. The investigator's intellectual property is being used in the study.	no			yes	Microsurgical Innovations	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00155905	Christian Yost	Principal Investigator	10048161	NETS: PROTECTION OR HARM IN NEONATAL INFLAMMATION AND INFECTION	The investigator's licensed intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00156830	Brandon Lawrence	Co-Investigator	IRB_00087670	Anterior versus Posterior Surgery for Isthmic Spondylolisthesis (I-Spondy)	The investigator reports significant financial interest in AO Spine North America, the sponsor of the project.	yes	AO Spine North America	\$10,000 to \$19,999	no			no	
CRV_00157132	K-T VARLEY	Principal Investigator	10047239	LONGITUDINAL MODELS OF BREAST CANCER FOR STUDYING MECHANISMS OF THERAPY RESPONSE AND RESISTANCE	The investigator reports significant financial interest with Kailos Genetics Inc., a non-publicly traded company which is helping to evaluate technology being studied. The investigator's licensed intellectual property will be used in the project.	yes	Kailos Genetics	\$20,000 to \$39,999	yes	Kailos Genetics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00157197	Kensaku Kawamoto	Principal Investigator	10060557	CLINICAL DECISION SUPPORT SYSTEM (CDSS) TO OPTIMIZE DISEASE MANAGEMENT	The investigator's intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00157220	Kensaku Kawamoto	Principal Investigator	IRB_00109162	Evaluation of an EHR-Integrated Dashboard for Diabetes Care	The investigator's intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00158639	Aaron Dewald	Principal Investigator	IRB_00145889	Using Visual Representations and Varied Context in Instructional Videos: Effects on Memory and Transfer	The investigator reports significant financial remuneration from Quimbee, Inc.(a non-publicly traded company) who will be providing access to their customer list for recruiting participants.	yes	Quimbee	over \$100,000	no			no	
CRV_00158644	Ryan O'Hara	Principal Investigator	10041825	Radiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Registry	The investigator reports significant financial interest from the study sponsor SIRTEX MEDICAL INC.	yes	SIRTEX MEDICAL INC	\$60,001 to \$79,999	no			no	
CRV_00158648	Ryan O'Hara	Principal Investigator	IRB_00091660	Radiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Study	The investigator reports significant financial interest from the study sponsor SIRTEX MEDICAL INC.	yes	SIRTEX MEDICAL INC	\$60,000 to \$79,999	no			no	
CRV_00159422	Phillip Warner	Co-Investigator	IRB_00109162	Evaluation of an EHR-Integrated Dashboard for Diabetes Care	The investigator's intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00159529	Robert Schlager	Co-Investigator	IRB_00142114	Understanding Susceptibility and Response to SARS-CoV-2 Infection in Children: A Metagenomics Approach	The investigator's licensed intellectual property will be used in the study. The investigator reports a significant financial interest in the licensing company, IDbyDNA.	yes	IDbyDNA	Over \$100,000	yes	IDbyDNA	Value cannot be readily determined	yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)						Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest							
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00159605	Andrew Merryweather	Principal Investigator	IRB_00147354	User Testing of a Robotic Adaptive Screen Mount for Eye Tracking Enabled Screens	The investigator's licensed intellectual property will be used in the research.	no			no			yes	Value cannot be readily determined
CRV_00159692	Bradley Katz	Principal Investigator	IRB_00147264	Pilot Study of Avulux Lenses for the Treatment of Sharp-Edge Eye Syndrome	The investigator has a significant financial interest in Axon Optics, LLC, who will provide the glasses for the study. The investigator's licensed intellectual property will be used in the study.	no			yes	Axon Optics, LLC	Value cannot be readily determined	yes	
CRV_00159871	Sergiusz Wesolowski	Data Analyst	IRB_00136167	EXEMPTION UMBRELLA: Assembling de-identified machine learning datasets for outcomes research.	The investigator's licensed intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00161151	JAN PIERCE	Key Personnel	IRB_00067855	Platelet Lysate Derived Material for use as a Fetal Serum Substitute	The investigator's licensed intellectual property will be used in the study. The investigator has a significant financial interest with the licensing company, Eliksa.	yes	Eliksa	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00161666	Ross Whitaker	Co-Investigator	10060076	A MULTICITY STUDY OF WINTERTIME INVERSIONS AND ACUTE CARDIORESPIRATORY HEALTH EVENTS IN THE WESTERN U.S.	The investigator reports a significant financial interest in Tetrad: Sensor Network Solutions, LLC (a non-publicly traded company). They will be collecting publicly available data from the Tetrad website.	no			yes	Tetrad: Sensor Network Solutions, LLC	Value cannot be readily determined	no	
CRV_00162052	Gordon Lemmon	Research Coordinator	IRB_00096804	Genetics of Epilepsy Study	The investigator's licensed intellectual property will be used in this project. The investigator reports a significant financial interest in Backdrop Health, which will be performing testing.	no			yes	Backdrop Health	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00162661	James Patten	Key Personnel	10060158	TRANSFORMING UINTA BASIN EARTH MATERIALS FOR ADVANCED PRODUCTS (TUBE-MAP)	James Patten reports a significant financial interest in Red Leaf Resources, a company that holds leases in the Uintah Basin and that could potentially benefit from the results of this project. James Patten's work on this project is independent of Red Leaf Resources and is being conducted as a private consultant.	yes	Red Leaf Resources	Over \$100,000	yes	Red Leaf Resources	Value cannot be readily determined	no	
CRV_00162743	John Ryan	Principal Investigator	10059220	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FINERENONE ON MORBIDITY AND MORTALITY IN PARTICIPANTS WITH HEART FAILURE (NYHA II-IV) AND LVEF >/= 40%	The investigator reports significant financial interest from Bayer Pharmaceuticals, the study sponsor.	yes	Bayer Pharmaceuticals	\$10,000 to \$19,999	no			no	
CRV_00163151	Kevin Brennan	Co-Investigator	IRB_00068751	Memantine for Enhanced Stroke Recovery	The investigator reports significant financial interest from AbbVie, the manufacturer of the study drug.	yes	Allergan Inc Abbvie Inc	\$5,000 to \$9,999 \$10,000 to \$19,999	no			no	
CRV_00164037	Mary Scholand	Principal Investigator	10040360	Bronchial Sample Collection for a Novel Genomic Test.	The investigator reports significant financial interest from the study sponsor Veracyte.	yes	Veracyte	\$5,000 to \$9,999	no			no	
CRV_00164082	Mary Scholand	Principal Investigator	IRB_00087753	BRAVE-1 Bronchial Sample Collection for a Novel Genomic Test	The investigator reports significant financial interest from the study sponsor Veracyte.	yes	Veracyte	\$5,000 to \$9,999	no			no	
CRV_00164384	Kathryn Peterson	Principal Investigator	10061765	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY OF DUPILUMAB (ANTI-IL4RA) IN SUBJECTS WITH EOSINOPHILIC GASTRITIS	The investigator reports significant financial interest in Sanofi-Regeneron, the manufacturer of the study drug.	yes	Sanofi-Regeneron		no			no	
CRV_00164591	Jeremy Gilliland	Co-Investigator	IRB_00145076	Mid-term Survival of the Insignia Stem in Primary Total Hip Arthroplasty	The investigator reports significant financial interest in the study sponsor Stryker.	yes	Stryker	\$10,000 to \$19,999	no			no	

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)

Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00164960	ALISTAIR WARD	Co-Investigator	IRB_00150395	A web software system supporting team-based, longitudinal genomic diagnostic care	The investigator reports significant financial interest in Frameshift Labs, LLC a non-publicly traded company that will be involved with the study. The investigator's licensed intellectual property will be used in the study.	yes	Frameshift Labs	Over \$100,000	yes	Frameshift Labs	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00165056	Gabor Marth	Principal Investigator	IRB_00150395	A web software system supporting team-based, longitudinal genomic diagnostic care	The investigator reports significant financial interest in Frameshift Labs, LLC a non-publicly traded company that will be involved with the study. The investigator's licensed intellectual property will be used in the study.	no			yes	Frameshift Labs	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00165759	Florian Solzbacher	Principal Investigator	10060302	A WIRELESS MICRO-ECOG PROSTHESIS FOR SPEECH	The investigator reports significant financial interest in Blackrock Microsystems Europe GmbH and Blackrock Microsystems, who is involved in the study.	yes	Blackrock Microsystems	Over \$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	no	
CRV_00166052	J. Robinson Singleton	Principal Investigator	IRB_00144933	Diagnostic and Screening Performance of NeuroSense	The investigator reports significant equity from NeuroSense LLC, which is involved in the study. The investigator's intellectual property is being used in the study.	no			yes	NeuroSense LLC	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00167445	Mitchell Wulfman	Key Personnel	IRB_00140200	Mental Health Prevention and Promotion: Leveraging positive psychological interventions and social entrepreneurship to build resilience and well-being in college students	The investigator reports significant financial interest in the company Wellbeing Elevated, Inc. Well-Being is delivering the mental health programming in group sessions.	yes	Wellbeing Elevated, Inc.	Over \$100,000	yes	Wellbeing Elevated, Inc.	Value cannot be readily determined	no	
CRV_00167857	Christian Yost	Principal Investigator	10057512	SELECTION OF A LEAD CANDIDATE FOR THE DEVELOPMENT OF A NOVEL ANTI-INFLAMMATORY THERAPEUTIC	The investigator's licensed intellectual property is being used in the project.	no			no			yes	Value cannot be readily determined
CRV_00168676	Roger Freedman	Co-Investigator	IRB_00147829	Aveir Dual-Chamber Leadless I2I IDE Study	The investigator reports significant financial interest in Abbott Laboratories, the study sponsor.	yes	Abbott Laboratories	\$5,000 to \$9,999	no			no	
CRV_00168757	Jill Shea	Principal Investigator	10063463	NOVEL SUSTAINED RELEASE LOCAL ANESTHETIC WOUND DRESSING FOR SUPERFICIAL AND PARTIAL-THICKNESS DERMAL INJURIES	This investigator reports significant financial interest in the study sponsor, Rebel Medicine, a non-publicly traded company.	no			yes	Rebel Medicine	Value cannot be readily determined	no	
CRV_00168888	Gabor Marth	Principal Investigator	10061038	CALYPSO: A WEB SOFTWARE SYSTEM SUPPORTING TEAM-BASED, LONGITUDINAL GENOMIC DIAGNOSTIC CARE	The investigator reports significant financial interest in Frameshift Labs, LLC which will be involved in this project. The investigator's licensed intellectual property will be used in this project.	no			yes	Frameshift Labs	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00169045	Karen Eilbeck	Data Analyst	IRB_00021614	Endometriosis: Natural History, Diagnosis, and Outcomes (ENDO)	The investigator's intellectual property is being used in the research. The investigator has a significant financial interest in Fabric Genomics, the licensor of the technology.	yes	Fabric Genomics	\$80,000 to \$99,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00169733	Allison Payne	Co-Investigator	IRB_00148669	Breast MRgFUS: A Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00169820	Christian Yost	Co-Investigator	10060581	HUMAN PLATELET PAR4: NOVEL ACTIVATION, INTERINDIVIDUAL VARIATION, AND NEUTROPHIL INTERACTIONS IN VIVO AND IN VITRO	This investigator's intellectual property is being used in the project.	no			no			yes	Value cannot be readily determined
CRV_00170952	Benjamin Steinberg	Principal Investigator	10061417	SOTALOL REGISTRY STUDY	Investigator reports a significant financial interest in AltaThera, the study sponsor.	yes	Altathera	\$5,000 to \$9,999	no			no	

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)

Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00171091	Julia Batten	Co-Investigator	IRB_00140944	Seagen SGNTUC-019>>A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations	The investigator has a significant financial interest in the study sponsor Seagen.	yes	Seagen	\$5,000 to \$9,999	no			no	
CRV_00171355	Gordon Lemmon	Data Analyst	IRB_00103256	Role of Genetic and Epigenetic Factors in Cardiac Failure and Recovery	The investigator's intellectual property will be used in the study. The investigator has a significant financial interest in Backdrop Health, the licenser of the technology.	no			no			yes	Value cannot be readily determined
CRV_00171588	Gregory Clark	Co-Investigator	10063790	OPTIMAL FEATURE GENERATION FOR PERIPHERAL NERVE INTERFACES TO GUIDE THE DEVELOPMENT OF DEXTEROUS NEUROPROSTHESES	The investigator's licensed intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00172223	David Shields	Co-Investigator	IRB_00109162	Evaluation of an EHR-Integrated Dashboard for Diabetes Care	The investigator's intellectual property is being used in the project.	no			no			yes	Value cannot be readily determined
CRV_00172239	Craig Kilburg	Co-Investigator	IRB_00116693	STERLING Registry (CNV_2017_01): A Prospective, Multi-Center, Single Arm Study to obtain "real world" clinical data and characterize the acute and long term performance of the MICRUSFRAME and GALAXY coils including the pulserider aneurysm neck reconstruc	The investigator has a significant financial interest in the study sponsor Cerenovus.	yes	Cerenovus	\$5,000 to \$9,999	no			no	
CRV_00172293	Shannon Gadd	Principal Investigator	IRB_00138165	Assessing Impact of a Pharmacist in a Private Primary Care Practice with Payer Collaboration: A Quadruple Aim Approach	The investigator reports a significant financial interest in Granger Medical Clinic, where participants will be recruited.	yes	Granger Medical Clinic	\$40,000 to \$59,999	no			no	
CRV_00172378	Julia Batten	Co-Investigator	IRB_00122013	Nektar 17-214-09 / CA045002>>A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma	The investigator reports a significant financial interest with Exelixis, Inc, which manufactures Cabozantinib.	yes	Exelixis, Inc	\$10,000 to \$19,999	no			no	
CRV_00172397	Craig Kilburg	Co-Investigator	IRB_00150552	Middle Meningeal Artery Embolization for the Treatment of SuBduRal HemAtomAs with TRUFILL® n-BCA (MEMBRANE)	The investigator reports a significant financial interest with the study sponsor Cerenovus.	yes	Cerenovus	\$5,000 to \$9,999	no			no	
CRV_00172495	Diana Brixner	Co-Investigator	IRB_00153467	Real World Effectiveness of the Omnipod DASH Insulin Delivery System in Lowering HbA1C and Hypoglycemia Related Healthcare Spending	The investigator has a significant financial interest in the study sponsor Insulet Corporation.	yes	Insulet Corporation	\$20,000 to \$39,999	no			no	
CRV_00172515	Phillip Warner	Key Personnel	IRB_00128991	Design, Implementation and Evaluation of Scalable Decision Support for Chronic Disease Management and Health Maintenance	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00172516	Salvador Rodriguez	Key Personnel	IRB_00128991	Design, Implementation and Evaluation of Scalable Decision Support for Chronic Disease Management and Health Maintenance	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00172518	David Shields	Co-Investigator	IRB_00128991	Design, Implementation and Evaluation of Scalable Decision Support for Chronic Disease Management and Health Maintenance	The investigator's intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)					Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00172525	Scott Summers	Principal Investigator	10062553	THE ROLE OF CERAMIDES IN THE PANCREATIC BETA CELL	The investigator has a significant financial interest in Centaurus Therapeutics, which provides the compounds used in the study.	yes	Centaurus Therapeutics	\$10,000 to \$19,999	yes	Centaurus Therapeutics	Value cannot be readily determined	no	
CRV_00172830	Russell Butterfield	Principal Investigator	IRB_00131062	EMBARC: A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARC)	The investigator reports a significant financial interest in the study sponsor Sarepta Therapeutics.	yes	Sarepta Therapeutics	\$5,000 to \$9,999	no			no	
CRV_00172838	Russell Butterfield	Principal Investigator	10055142	LONG-TERM, OPEN-LABEL EXTENSION STUDY FOR PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY ENROLLED IN CLINICAL TRIALS EVALUATING CASIMERSEN OR GOLODIRSEN	The investigator a reports significant financial interest with the study sponsor Sarepta Therapeutics.	yes	Sarepta Therapeutics	\$5,000 to \$9,999	no			no	
CRV_00172847	Russell Butterfield	Principal Investigator	10056662	A MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SYSTEMIC GENE DELIVERY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF SRP-9001 IN SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY WHO ARE AGED 4-7 YEARS	The investigator reports significant financial interest in Sarepta Therapeutics, the sponsor of the project.	yes	Sarepta Therapeutics	\$5,000 to \$9,999	no			no	
CRV_00172913	Russell Butterfield	Principal Investigator	IRB_00083978	A Double-Blind, Placebo-Controlled, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients with Duchenne Muscular Dystrophy	The investigator reports a significant financial interest from the study sponsor Sarepta Therapeutics.	yes	Sarepta	\$5,000 to \$9,999	no			no	
CRV_00172914	Russell Butterfield	Principal Investigator	IRB_00127904	Long-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen	The investigator reports a significant financial interest in the study sponsor Sarepta Therapeutics.	yes	Sarepta Therapeutics	\$5,000 to \$9,999	no			no	
CRV_00172928	Claude Nanjo	Key Personnel	IRB_00128991	Design, Implementation and Evaluation of Scalable Decision Support for Chronic Disease Management and Health Maintenance	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00172934	Peter Chalmers	Principal Investigator	10061174	OUTCOMES OF SHOULDER ARTHROPLASTY USING A DEPUY TOTAL OR HEMI SHOULDER SYSTEM	The investigator has a significant financial interest in the study sponsor Depuy Synthes.	yes	Depuy Synthes Mitek	\$20,000 to \$39,999	no			no	
CRV_00172949	Eric Garland	Principal Investigator	IRB_00133405	Neural Mechanisms of Meditation-Based Interventions for Chronic Low Back Pain	The investigator's intellectual property will be used in the study. This technology is licensed to BehaVR, a non-publicly traded company in which the investigator has a significant financial interest.	no			no			yes	Value cannot be readily determined
CRV_00172975	Benjamin Steinberg	Principal Investigator	IRB_00147440	Prospective Evaluation Analysis and Kinetics of IV Sotalol (PEAKS Registry)	The investigator reports a significant financial interest in AltaThera, the study sponsor.	yes	AltaThera	\$5,000 to \$9,999	no			no	
CRV_00172989	VANESSA REDECKE	Co-Investigator	IRB_00153086	Comparison of a Point of Care, Finger Stick test for COVID-19 antibodies with currently approved serology methods	The investigator's intellectual property will be used in the project. The investigator reports a significant financial interest in Nanospot.ai, a non-publicly traded company which will be commercializing the technology.	no			yes	Nanospot.ai	Value cannot be readily determined	yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)					Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00173000	Michael Flynn	Key Personnel	IRB_00128991	Design, Implementation and Evaluation of Scalable Decision Support for Chronic Disease Management and Health Maintenance	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00173106	Russell Butterfield	Principal Investigator	10063836	SRP-9001-303: A PHASE 3, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SYSTEMIC GENE TRANSFER THERAPY STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SRP- 9001 IN NON-AMBULATORY AND AMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY	The investigator has a significant financial interest in Sarepta Therapeutics, the maker of the drug, SRP-9001, being evaluated.	yes	Sarepta Therapeutics	\$5,000 to \$9,999	no			no	
CRV_00173118	HANS HAECKER	Co-Investigator	IRB_00153086	Comparison of a Point of Care, Finger Stick test for COVID-19 antibodies with currently approved serology methods	The investigator's intellectual property will be used in the project. The investigator reports a significant financial interest in Nanospot.ai, a non-publicly traded company which will be commercializing the technology.	no			yes	Nanospot.ai	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00173204	Christopher Pelt	Principal Investigator	IRB_00075446	Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty	The investigator's financial interests may be related to the broad aims of this research.	yes	Total Joint Orthopaedics; Smith and Nephew	\$20,000 to \$39,999 \$5,000 to \$9,999	yes	Joint Development, Inc.	Value cannot be readily determined	no	
CRV_00173279	Zachary Hillman	Data Analyst	IRB_00110994	Transcutaneous Stimulation for Haptic Feedback	The investigator reports significant financial interest with the Biological Input Output Systems, which will be involved in the study.	yes	Biological Input Output Systems	\$10,000 to \$19,999	no			no	
CRV_00173280	Zachary Hillman	Data Analyst	IRB_00098851	Improving myoelectric prosthetic and orthotic limb control using predictive regression algorithms and high-count surface electrodes	The investigator reports significant financial interest with the Biological Input Output Systems, which will be involved in the study.	yes	Biological Input Output Systems	\$10,000 to \$19,999	no			no	
CRV_00173608	John Ryan	Principal Investigator	IRB_00139554	(FINEARTS) A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fra	The investigator has a significant financial interest in the study sponsor Bayer.	yes	Bayer Pharmaceuticals	\$10,000 to \$19,999	no			no	
CRV_00173708	Gregory Clark	Co-Investigator	IRB_00124231	Can an array of micro-electrodes implanted in a human nerve record neural signals and provide sensory feedback useful for controlling a prosthetic device? (HAPTIX FDA IDE Approval)	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00174136	Jacob George	Principal Investigator	IRB_00124231	Can an array of micro-electrodes implanted in a human nerve record neural signals and provide sensory feedback useful for controlling a prosthetic device? (HAPTIX FDA IDE Approval)	The investigator reports a significant financial interest in BIOS, a sponsor of the project.	yes	BIOS	\$5,000 to \$9,999	no			no	
CRV_00174271	Julia Batten	Co-Investigator	IRB_00143008	SWOG S1931 (NCI CIRB) >> Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (Probe Trial)	The investigator reports a significant financial interest in EMD Serono, the manufacturer of study drug Avelumab.	yes	EMD Serono	\$5,000 to \$9,999	no			no	

Individual Conflict of Interest Public Disclosures as of August 19, 2022 (if required for public disclosure)

Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00174325	Florian Solzbacher	Co-Investigator	10065133	PASSIVE INTRACRANIAL PRESSURE SENSOR FOR HYDROCEPHALUS SHUNTS AND CRANIOPLASTY IMPLANTS WITH ULTRASOUND READOUT	The investigator's intellectual property is being used in the study. The technology has been licensed to Sentiomed, a non-publicly traded company in which the investigator reports a significant financial interest. Sentiomed is a sponsor of this project.	no			yes	Sentiomed	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00175075	Mark Yandell	Co-Investigator	IRB_00142987	ReSeq: Reanalysis of clinical rapid whole genomes	The investigator's intellectual property will be used in the study. The investigator reports a significant financial interest in Fabric Genomics and Backdrop Heath, companies which have licensed the technology.	yes	Fabric Genomics	\$80,000 to \$99,999	yes	Fabric Genomics Backdrop Health Inc.	Value cannot be readily determined Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00175088	Jill Shea	Principal Investigator	10065448	SUPPLEMENT: DEVELOPMENT OF A NOVEL SUSTAINED RELEASE LOCAL ANESTHETIC WOUND DRESSING FOR PARTIAL-THICKNESS DERMAL INJURIES	The investigator reports a significant financial interest with the study sponsor, Rebel Medicine.	no			yes	Rebel Medicine	Value cannot be readily determined	no	
CRV_00175093	Mary Scholand	Principal Investigator	10059343	A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)	The investigator reports a significant financial interest with Genentech, a subsidiary of the study sponsor Hoffman-LaRoche.	yes	Genentech	\$5,000 to \$9,999	no			no	
CRV_00175098	ALANA WELM	Principal Investigator	IRB_00156327	Development and use of patient-derived xenograft and organoid models	Models generated by this project may be imminently licensed as tangible property.	no			no			yes	Value cannot be readily determined
CRV_00175099	Bryan Welm	Co-Investigator	IRB_00156327	Development and use of patient-derived xenograft and organoid models	Models generated by this project may be imminently licensed as tangible property.	no			no			yes	Value cannot be readily determined
CRV_00175154	Nathan Hatton	Co-Investigator	IRB_00132922	A Phase I/II Randomized Double-Blinded Placebo-Controlled Clinical Trial to Determine Safety and Feasibility of Using an Acellular Sterile Filtered Amniotic Fluid as a Treatment for COVID-19 Patients	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00175438	Bryan Welm	Co-Investigator	10062203	VALIDATION OF THE MHC II IMMUNE ACTIVATION ASSAY IN BREAST CANCER	Models generated by this project may be imminently licensed as tangible property.	no			no			yes	Value cannot be readily determined
CRV_00175557	Edgar Hernandez	Data Analyst	IRB_00142987	ReSeq: Reanalysis of clinical rapid whole genomes	The investigator reports a significant financial interest in Fabric Genomics, a company which produces tools being used in the study.	yes	Fabric Genomics	\$5,000 to \$9,999	no			no	
CRV_00176142	Michael Kay	Principal Investigator	10062103	CHEETAH CENTER FOR THE STRUCTURAL BIOLOGY OF HIV INFECTION, RESTRICTION, AND VIRAL DYNAMICS	The investigator's intellectual property will be used in this project. The investigator has a significant financial interest in the licensing company, Navigen.	no			yes	Navigen, Inc	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00176156	Debra Eckert	Co-Investigator	10062103	CHEETAH CENTER FOR THE STRUCTURAL BIOLOGY OF HIV INFECTION, RESTRICTION, AND VIRAL DYNAMICS	The investigator's intellectual property will be used in the study. The investigator reports a significant financial interest in Navigen, the licensor of the technology.	no			yes	Navigen, Inc.	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00176732	Daniel Scoles	Other (Please Indicate Below)	IRB_00092440	Genetic, Biological and Functional Studies of Neurodegenerative Diseases	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined